Tokushima University / Educator and Researcher Directory --- Fukawa, Tomoya

Field of Study

Subject of Study

Book / Paper

Book:

1.	Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 膀胱への穿通胎盤にて帝王切開，子宮全摘，膀胱部分切除術施行後に骨盤内尿腫を形成し，真性尿失禁をきたした1例, Oct. 2018.
2.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 間質性膀胱炎が疑われ，膀胱水圧拡張術が診断の契機となった膀胱アミロイドーシスの1例, Dec. 2017.

Academic Paper (Judged Full Paper):

1.	Yutaro Sasaki, Masayuki Takahashi, Kei Daizumoto, Keito Shiozaki, Tomoya Fukawa and Hiroomi Kanayama : Assistent guide short: A new device for facilitating ureteric stenting in women., International Journal of Urology, 2023. (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.15252 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37504506 ● Summary page in Scopus @ Elsevier: 2-s2.0-85165960914 (DOI: 10.1111/iju.15252, PubMed: 37504506, Elsevier: Scopus)
2.	Yutaro Sasaki, Kei Daizumoto, Kyotaro Fukuta, Keito Shiozaki, Mitsuki Nishiyama, Seiya Utsunomiya, Saki Kobayashi, Kosuke Seto, Yoshiteru Ueno, Ryotaro Tomida, Yoshito Kusuhara, Tomoya Fukawa, Ryoichi Nakanishi, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki and Masayuki Takahashi : Lymph node dissection during radical cystectomy for bladder cancer: A two-center comparative study of robotic versus open surgery., Asian Journal of Endoscopic Surgery, 2023. (Summary) This study was performed to evaluate the safety and efficacy of lymph node dissection (LND) during robot-assisted radical cystectomy (RARC) compared with open radical cystectomy (ORC). From October 2003 to December 2021, 122 patients underwent LND during RARC and 103 patients underwent LND during ORC at Tokushima University Hospital and Tokushima Prefectural Central Hospital. We investigated the safety and efficacy of LND during RARC by comparing the surgical and oncological outcomes between the two groups. The patients were significantly older in the RARC than the ORC group. The operative time was significantly shorter and the estimated blood loss was significantly lower in the RARC than the ORC group. Although the lymph node yield was significantly higher in the RARC than the ORC group, there was no significant difference in lymph node positivity between the groups. There was no significant difference in the incidence of local recurrence or distant metastasis between the two groups. The 5-year survival rates (overall survival, cancer-specific survival, and recurrence-free survival) were not different between the RARC and ORC groups. This study suggests that the surgical and oncological safety and efficacy of LND during RARC are greater than those of LND during ORC. We believe that LND during RARC is a higher-quality procedure than LND during ORC. (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.13234 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37489628 ● Summary page in Scopus @ Elsevier: 2-s2.0-85165549223 (DOI: 10.1111/ases.13234, PubMed: 37489628, Elsevier: Scopus)
3.	Masayuki Takahashi, Kei Daizumoto, Tomoya Fukawa, Yayoi Fukuhara, Yoshimi Bando, Minoru Kowada, Tsogt-Ochir Dondoo, Yutaro Sasaki, Ryotaro Tomida, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hisanori Uehara and Hiroomi Kanayama : Insulin receptor expression to predict resistance to axitinib and elucidation of the underlying molecular mechanism in metastatic renal cell carcinoma., British Journal of Cancer, 2023. (Summary) Decreased INSR in RCC could be a biomarker to predict axitinib resistance. Regarding the resistant mechanism, vascular endothelial cells with decreased INSR in RCC may secrete interferon-β and induce PD-L1. (Link to Publication Site) ● Publication site (DOI): 10.1038/s41416-023-02325-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37355721 ● Search Scopus @ Elsevier (PMID): 37355721 ● Search Scopus @ Elsevier (DOI): 10.1038/s41416-023-02325-8 (DOI: 10.1038/s41416-023-02325-8, PubMed: 37355721)
4.	Katsuhito Hori, Yutaro Sasaki, Keito Shiozaki, Fumiya Kadoriku, Kei Daizumoto, Ryotaro Tomida, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi, Yoshihiro Tsuruo and Hiroomi Kanayama : Efficacy of fresh-frozen cadaveric surgical training for arteriovenous fistula in vascular access., The Journal of Vascular Access, 2023. (Summary) CST for AVF creation is useful for surgical education because it enables learning of surgical techniques that are almost equivalent to those in living bodies. In addition, this study suggested that CST not only contributes to the improvement of surgical skills of young surgeons but also promotes the reduction of anxiety and stress about AVF creation. (Link to Publication Site) ● Publication site (DOI): 10.1177/11297298231169056 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37070175 ● Search Scopus @ Elsevier (PMID): 37070175 ● Search Scopus @ Elsevier (DOI): 10.1177/11297298231169056 (DOI: 10.1177/11297298231169056, PubMed: 37070175)
5.	Yutaro Sasaki, Masayuki Takahashi, Kyotaro Fukuta, Keito Shiozaki, Kei Daizumoto, Yoshiteru Ueno, Ryotaro Tomida, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki and Hiroomi Kanayama : Assistent guide: A novel device for ureteral stent placement in robot-assisted intracorporeal ileal conduit., The International Journal of Medical Robotics + Computer Assisted Surgery : MRCAS, Vol.19, No.4, 2023. (Summary) We showed the safety and efficacy of the Assistent guide for ureteral stent placement in RICIC. (Keyword) Humans / Cystectomy / robotics / Urinary Diversion / Stents / Ureteral Obstruction / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1002/rcs.2513 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36840720 ● Summary page in Scopus @ Elsevier: 2-s2.0-85149381419 (DOI: 10.1002/rcs.2513, PubMed: 36840720, Elsevier: Scopus)
6.	Kunihisa Yamaguchi, Keisuke Ozaki, Tomoya Fukawa, Yutaro Sasaki, Shu Wakino and Masayuki Takahashi : Drug-induced de novo thrombotic microangiopathy diagnosed 2 years after renal transplantation: A case report and literature review, Renal Replacement Therapy, Vol.9, 1-6, 2023. (Link to Publication Site) ● Publication site (DOI): 10.1186/s41100-022-00453-0 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1186/s41100-022-00453-0 (DOI: 10.1186/s41100-022-00453-0)
7.	Keisuke Ozaki, Tomoya Fukawa, Kei Daizumoto, Yutaro Sasaki, Yoshiteru Ueno, Megumi Tsuda, Takayuki Uchida, Yoshito Kusuhara, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : The impact of nutritional status and changes of body composition on the prognosis of metastatic renal cell carcinoma patients., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 80-87, 2023. (Summary) Nutritional status of mRCC patients may predict changes in body composition and be associated with their prognosis. J. Med. Invest. 70 : 80-87, February, 2023. (Keyword) Humans / Carcinoma, Renal Cell / Kidney Neoplasms / Nutritional Status / Prognosis / Body Composition / Retrospective Studies / Protein Kinase Inhibitors (Tokushima University Institutional Repository) ● Metadata: 118311 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.80 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164748 ● Search Scopus @ Elsevier (PMID): 37164748 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.80 (Tokushima University Institutional Repository: 118311, DOI: 10.2152/jmi.70.80, PubMed: 37164748)
8.	Yoshiteru Ueno, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Ryotaro Tomida, Yasuyo Yamamoto, Kunihisa Yamaguchi, Chisato Tonoiso, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima, Masayuki Takahashi and Hiro-omi Kanayama : Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer., In Vivo, Vol.37, No.2, 738-746, 2023. (Summary) PSA levels at 5 years post-treatment were associated with long-term recurrence of localized prostate cancer, which can help alleviate patient anxiety concerning prostate cancer recurrence if PSA levels remain low at 5 years after LDR-BT. (Keyword) Male / Humans / Prostate-Specific Antigen / Brachytherapy / Cohort Studies / East Asian People / Prostatic Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.13136 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36881090 ● Search Scopus @ Elsevier (PMID): 36881090 ● Search Scopus @ Elsevier (DOI): 10.21873/invivo.13136 (DOI: 10.21873/invivo.13136, PubMed: 36881090)
9.	尾﨑啓介, Kunihisa Yamaguchi, 多田亜沙香, Tomoya Fukawa, Yutaro Sasaki, Yoshito Kusuhara, Yasuyo Yamamoto, 林秀樹, Masayuki Takahashi, Yoshihiro Tsuruo, 橋本寛文 and Hiro-omi Kanayama : 未固定凍結遺体を用いた心停止下献腎摘出教育の試み, 日本臨床腎移植学会雑誌, Vol.10, No.2, 259-261, 2022.
10.	Keito Shiozaki, Kazuyoshi Izumi, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Yasuo Kawanishi and Hiroomi Kanayama : Comparison of robot-assisted partial nephrectomy with soft coagulation and double-layer technique for complex and non-complex tumors., International Journal of Urology, Vol.30, No.3, 281-288, 2022. (Summary) Single-layer suturing with soft coagulation achieves renal function and perioperative outcomes comparable to those of double-layer suturing regardless of complexity. (Keyword) Humans / Robotics / Retrospective Studies / Nephrectomy / Kidney / Kidney Neoplasms / Robotic Surgical Procedures / Treatment Outcome (Tokushima University Institutional Repository) ● Metadata: 118156 (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.15112 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36448456 ● Search Scopus @ Elsevier (PMID): 36448456 ● Search Scopus @ Elsevier (DOI): 10.1111/iju.15112 (Tokushima University Institutional Repository: 118156, DOI: 10.1111/iju.15112, PubMed: 36448456)
11.	Fumiya Kadoriku, Yutaro Sasaki, Kyotaro Fukuta, Yuichiro Atagi, Keito Shiozaki, Kei Daizumoto, Ryotaro Tomida, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yutaka Yanagihara, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Sadamu Yamashi, Masaharu Kan and Hiroomi Kanayama : A propensity score matching study on robot-assisted radical cystectomy for older patients: comparison of intracorporeal ileal conduit and cutaneous ureterostomy., BMC Urology, Vol.22, No.1, 2022. (Summary) In older patients, the ICIC group showed non-inferior surgical and oncological outcomes compared with the CUS group. Urinary diversion following RARC in older patients should be carefully selected by considering not only the age but also the general condition (including comorbidities) of the patient. (Keyword) Aged / Humans / Cystectomy / Postoperative Complications / Propensity Score / Retrospective Studies / Robotic Surgical Procedures / robotics / Treatment Outcome / Ureterostomy / Urinary Bladder Neoplasms / Urinary Diversion (Tokushima University Institutional Repository) ● Metadata: 118559 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12894-022-01123-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36344965 ● Summary page in Scopus @ Elsevier: 2-s2.0-85141380657 (Tokushima University Institutional Repository: 118559, DOI: 10.1186/s12894-022-01123-3, PubMed: 36344965, Elsevier: Scopus)
12.	Kazutoshi Fujita, Go Kimura, Toyonori Tsuzuki, Taigo Kato, Eri Banno, Akira Kazama, Ryo Yamashita, Yuto Matsushita, Daisuke Ishii, Tomoya Fukawa, Yuki Nakagawa, Tamaki Fukuyama, Fumikazu Sano, Yukihiro Kondo and Hirotsugu Uemura : The Association of Tumor Immune Microenvironment of the Primary Lesion with Time to Metastasis in Patients with Renal Cell Carcinoma: A Retrospective Analysis., Cancers, Vol.14, No.21, 2022. (Summary) Biological or immunological differences in primary lesions between synchronous and metachronous metastatic renal cell carcinoma (mRCC) have been reported. However, the association between the tumor immune microenvironment (TIME) of primary lesions and time to metastasis remains unknown. We investigated the differences in the TIME of primary lesions based on time intervals to metastasis, mainly between the synchronous group (SG; metastasis within 3 months) and metachronous group (MG; metastasis after 3 months), and its association with clinicopathological parameters in patients with mRCC. Overall, 568 patients treated first-line with vascular endothelial growth factor receptor inhibitors comprised the analysis population (SG: N = 307 [54.0%]; MG: N = 261 [46.0%]). SG had a higher proportion of patients with poor prognostic pathological feature tumors: WHO/ISUP grade 4, necrosis, lymphovascular invasion, infiltrative growth pattern, and sarcomatoid differentiation. Regarding the TIME, more immunogenic features were seen in SG than MG, with a higher PD-L1 positivity and a lower proportion of the desert phenotype. This is the first study to examine the differences in the TIME of primary lesions in patients with mRCC based on the time intervals to metastasis. The TIME of primary lesions could affect the time to metastasis. (Tokushima University Institutional Repository) ● Metadata: 118574 (Link to Publication Site) ● Publication site (DOI): 10.3390/cancers14215258 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36358675 ● Search Scopus @ Elsevier (PMID): 36358675 ● Search Scopus @ Elsevier (DOI): 10.3390/cancers14215258 (Tokushima University Institutional Repository: 118574, DOI: 10.3390/cancers14215258, PubMed: 36358675)
13.	Kouki Tada, Kei Daizumoto, Masayuki Takahashi, Hisanori Uehara, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment., IJU Case Reports, Vol.6, No.1, 41-44, 2022. (Summary) Sunitinib after an IO-drug showed a significant effect in spite of only slight efficacy with other VEGFR-TKIs, which may have occurred through the alteration of the immunological microenvironment. (Tokushima University Institutional Repository) ● Metadata: 118791 (Link to Publication Site) ● Publication site (DOI): 10.1002/iju5.12545 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36605682 ● Search Scopus @ Elsevier (PMID): 36605682 ● Search Scopus @ Elsevier (DOI): 10.1002/iju5.12545 (Tokushima University Institutional Repository: 118791, DOI: 10.1002/iju5.12545, PubMed: 36605682)
14.	ANAYT ULLA, Kanae Osaki, Mizanur Md Rahman, Reiko Nakao, Takayuki Uchida, Isafumi Maru, Kazuaki Mawatari, Tomoya Fukawa, Hiro-omi Kanayama, Iori Sakakibara, Katsuya Hirasaka and Takeshi Nikawa : Morin improves dexamethasone-induced muscle atrophy by modulating atrophy-related genes and oxidative stress in female mice., Bioscience, Biotechnology, and Biochemistry, Vol.86, No.10, 1448-1458, 2022. (Summary) This study investigated the effect of morin, a flavonoid, on dexamethasone-induced muscle atrophy in C57BL/6J female mice. Dexamethasone (10 mg/kg body weight) for 10 days significantly reduced body weight, gastrocnemius and tibialis anterior muscle mass, and muscle protein in mice. Dexamethasone significantly upregulated muscle atrophy-associated ubiquitin ligases, including atrogin-1 and MuRF-1, and the upstream transcription factors FoxO3a and Klf15. Additionally, dexamethasone significantly induced the expression of oxidative stress-sensitive ubiquitin ligase Cbl-b and the accumulation of the oxidative stress markers malondialdehyde and advanced protein oxidation products in both the plasma and skeletal muscle samples. Intriguingly, morin treatment (20 mg/kg body weight) for 17 days effectively attenuated the loss of muscle mass and muscle protein and suppressed the expression of ubiquitin ligases while reducing the expression of upstream transcriptional factors. Therefore, morin might act as a potential therapeutic agent to attenuate muscle atrophy by modulating atrophy-inducing genes and preventing oxidative stress. (Keyword) Animals / Body Weight / Dexamethasone / Female / Flavones / Malondialdehyde / Mice / Mice, Inbred C57BL / Muscle Proteins / Muscle, Skeletal / Muscular Atrophy / Oxidative Stress / Tripartite Motif Proteins / Ubiquitin-Protein Ligases (Link to Publication Site) ● Publication site (DOI): 10.1093/bbb/zbac140 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35977398 ● Search Scopus @ Elsevier (PMID): 35977398 ● Search Scopus @ Elsevier (DOI): 10.1093/bbb/zbac140 (DOI: 10.1093/bbb/zbac140, PubMed: 35977398)
15.	Kyotaro Fukuta, Keito Shiozaki, Ryoichi Nakanishi, Hirofumi Izaki, Eiji Kudo, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Leptomeningeal carcinomatosis in small cell carcinoma of the prostate., IJU Case Reports, Vol.5, No.6, 493-496, 2022. (Summary) Careful monitoring of the central nervous system should be considered in small cell carcinoma of the prostate patients. (Tokushima University Institutional Repository) ● Metadata: 118792 (Link to Publication Site) ● Publication site (DOI): 10.1002/iju5.12524 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36341201 ● Search Scopus @ Elsevier (PMID): 36341201 ● Search Scopus @ Elsevier (DOI): 10.1002/iju5.12524 (Tokushima University Institutional Repository: 118792, DOI: 10.1002/iju5.12524, PubMed: 36341201)
16.	K. Ozaki, Takashi Kawanaka, Tomoya Fukawa, Kei Daizumoto, Yutaro Sasaki, Megumi Tsuda, Yoshito Kusuhara, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Appropriate management reduces radiation exposure in daily urological practice, International Journal of Urology, 2022. (Summary) To identify and raise awareness of the radiation exposure of urologists due to X-ray fluoroscopic procedures in daily practice. This was a single-center, cohort study of 30 consecutive patients who underwent periodic percutaneous or transurethral replacements of urinary tract catheters. A total of 55 replacements every 3 months with cases aligned were performed by a single urologist. The urologist's radiation exposure and the incident dose to patients per case were measured with thermoluminescent dosimeters. In the latter 3-month period, the pulse fluoroscopy condition was changed from 15 to 7.5 pulses per second, and collimation was added to the field of view. In the analysis of all patients, the use of a modified pulse rate and collimation did not affect the fluoroscopy time, but it did significantly reduce the air kerma and dose area product; in addition, with respect to the medical exposure dose during percutaneous catheter replacement, fluoroscopy time was longer, but air kerma and dose area product showed significant decreases. As with decreases in medical exposure of patients, the equivalent dose for eye lenses of the urologist decreased from 1.2 mSv in the first 3-month period to 0.2 mSv in the second 3-month period. Similarly, the exposure dose for the extremities also decreased significantly, from 33.9 mSv to 8.1 mSv. Urologists are exposed to non-negligible amounts of radiation due to fluoroscopy. Appropriate management such as modified pulse fluoroscopy condition and precautions are required. (Tokushima University Institutional Repository) ● Metadata: 118219 (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.14971 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35851694 ● Search Scopus @ Elsevier (PMID): 35851694 ● Search Scopus @ Elsevier (DOI): 10.1111/iju.14971 (Tokushima University Institutional Repository: 118219, DOI: 10.1111/iju.14971, PubMed: 35851694)
17.	Yutaro Sasaki, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto and Hiro-omi Kanayama : Efficacy of the Mercedes-Benz closure technique for vaginal reconstruction in female robot-assisted radical cystectomy, Asian Journal of Endoscopic Surgery, 2022. (Summary) Vaginal reconstruction using the posterior vaginal wall is required following radical cystectomy in women with resection of the uterus, adnexa, and anterior vaginal wall. Roll closure and clamshell closure are two widely known techniques. Of these, clamshell closure is recommended because roll closure has a high likelihood of breakdown or a resultant canal that is too narrow for sexual intercourse. In clamshell closure, however, folding the posterior vaginal wall anteriorly can be difficult. Therefore, we devised Mercedes-Benz closure, in which the vaginal wall is sutured from three directions to form a Mercedes-Benz shape, for anastomosis without tension on the vaginal wall. The present study was performed to investigate the efficacy of this alternative surgical technique for vaginal reconstruction. Twenty-six patients who underwent vaginal reconstruction following robot-assisted radical cystectomy were divided into two groups: 15 underwent clamshell closure and 11 underwent Mercedes-Benz closure. The patients' characteristics and surgical outcomes were compared between the two groups. There were no significant differences in clinical characteristics, including age, body mass index, and prior abdominal surgery between the two groups. The median vaginal reconstruction time tended to be longer in the Mercedes-Benz closure group than in the clamshell closure group (35.0 vs. 27.0 min, p = 0.102). No complications associated with vaginal reconstruction were identified. The surgical outcomes were comparable between Mercedes-Benz closure and clamshell closure. If vaginal reconstruction with clamshell closure is difficult, Mercedes-Benz closure is a valuable alternative technique. (Link to Publication Site) ● Publication site (DOI): 10.1111/ases.13109 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35842843 ● Search Scopus @ Elsevier (PMID): 35842843 ● Search Scopus @ Elsevier (DOI): 10.1111/ases.13109 (DOI: 10.1111/ases.13109, PubMed: 35842843)
18.	Yusuke Fukatani, Kei Daizumoto, Fumiya Kadoriku, 山本拓, Yutaro Sasaki, 尾﨑啓介, 上野恵輝, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hiro-omi Kanayama, Mariko Niki and Hisanori Uehara : A Case of Pappilary Renal Cell Caircinoma which Responded Well to the Combination Therapy of Ipilimumab and Nivolumab --A CASE REPORT--, Acta Urologica Japonica, Vol.68, No.4, 107-111, 2022. (Summary) We report a case of papillary renal cell carcinoma that responded well to the combination of ipilimumab and nivolumab. The patient was a 68-year-old male who was being followed up for a small left renal mass without treatment. Two years later, computed tomography (CT) showed enlarged cervical and para-aortic lymph nodes, and lymph node biopsy suggested metastases of the cancer. After resection of the renal tumor, we performed pararenal aortic lymph node biopsy, and we diagnosed the case as papillary renal cell carcinoma type 1 with lymph node metastasis. The combination of ipilimumab and nivolumab each metastatic site showed regression on CT. Since immune-related adverse events occurred during the therapy nivolumab was discontinued, but partial response of the metastases was maintained. (Keyword) Papillary renal cell carcinoma / Ipilimumab and nivolumab / 494.9 (Link to Publication Site) ● Publication site (DOI): 10.14989/actauroljap_68_4_107 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390573715168780160 ● Search Scopus @ Elsevier (DOI): 10.14989/actauroljap_68_4_107 (DOI: 10.14989/actauroljap_68_4_107, CiNii: 1390573715168780160)
19.	Kyotaro Fukuta, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Micropapillary Variant of Urothelial Carcinoma in a Hemodialysis Patient, Case Reports in Oncology, Vol.15, No.1, 462-468, 2022. (Summary) The micropapillary variant of urothelial carcinoma (MPUC) is an aggressive form of urothelial carcinoma with high metastatic potential and a poor prognosis. Although various therapies have been reported, there is still no established treatment strategy for MPUC due to its rarity. The incidence of urinary tract malignancies is higher in patients undergoing hemodialysis (HD) than in healthy individuals. Here, we report the case of an 82-year-old man on HD with end-stage kidney disease who visited our hospital for macrohematuria. Cystoscopy followed by computed tomography and urine cytology revealed a sessile papillary tumor around the left bladder wall. We performed transurethral resection of the bladder tumor. Based on histopathological and imaging findings indicative of clinical-stage T3N0M0 MPUC, we performed radical cystectomy. Histopathology revealed a pathological stage T4aN0M0 MPUC. Two months after the cystectomy, the patient complained of constipation and painful defecation due to local recurrence and rectal invasion. While colostomy was performed to improve defecation 3 months after cystectomy, he did not receive any chemotherapy due to his progressively worsening general condition. Six months after cystectomy, he died following rapid metastases. Our findings, in this case, confirm that bladder cancer in HD patients tends to be pathologically more advanced. Therefore, regular screening is recommended for its early detection in HD patients. (Tokushima University Institutional Repository) ● Metadata: 117427 (Link to Publication Site) ● Publication site (DOI): 10.1159/000524430 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35702563 ● Search Scopus @ Elsevier (PMID): 35702563 ● Search Scopus @ Elsevier (DOI): 10.1159/000524430 (Tokushima University Institutional Repository: 117427, DOI: 10.1159/000524430, PubMed: 35702563)
20.	Yutaro Sasaki, Masayuki Takahashi, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : The patient-side surgeon plays a key role in facilitating robot-assisted intracorporeal ileal conduit urinary diversion in men, Journal of Robotic Surgery, Vol.16, No.2, 437-444, 2022. (Summary) The influence of the console surgeon on the feasibility and outcome of various robot-assisted surgeries has been evaluated. These variables may be partially affected by the skills of the patient-side surgeon (PSS), but this has not been evaluated using objective data. This study aimed to describe the surgical techniques of the PSS in robot-assisted radical cystectomy (RARC) and intracorporeal ileal conduit (ICIC) urinary diversion and objectively examine the changes in surgical outcomes with increasing PSS experience. During a 3-year period, 28 men underwent RARC and ICIC urinary diversion. Clinical characteristics and surgical outcomes were compared between patients who underwent surgery early (first half group) or late in the study period (second half group). The pre-docking incision enabled easy specimen removal. The glove port technique widened the working space of the PSS. The stay suture allowed the PSS to control the distal portion of the conduit, facilitating the passage of the ureteral stents. During stoma creation, pneumoperitoneum pressure was lost by opening the abdominal cavity. To overcome this problem, the robotic arm was used to lift the abdominal wall to maintain the surgical field and facilitate the PSS procedure. Compared with the first half group, the second half group had significantly shorter times for urinary diversion (202 min vs 148 min, p < 0.001), ileal isolation and anastomosis (73 min vs 45 min, p < 0.001), and stenting (23.0 min vs 6.5 min, p < 0.001). As the experience of the PSS increased, the time of the PSS procedures decreased. (Keyword) Cystectomy / Humans / Male / Robotic Surgical Procedures / Robotics / Surgeons / Treatment Outcome / Urinary Bladder Neoplasms / Urinary Diversion (Tokushima University Institutional Repository) ● Metadata: 116363 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11701-021-01256-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34081290 ● Search Scopus @ Elsevier (PMID): 34081290 ● Search Scopus @ Elsevier (DOI): 10.1007/s11701-021-01256-x (Tokushima University Institutional Repository: 116363, DOI: 10.1007/s11701-021-01256-x, PubMed: 34081290)
21.	Kyotaro Fukuta, Keito Shiozaki, Saki Kobayashi, Ryoichi Nakanishi, Hirofumi Izaki, Kazuya Kanda, Tohru Inai, Eiji Kudo, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : Poor Outcome due to the Plasmacytoid Variant of Urothelial Carcinoma, Case Reports in Oncology, Vol.15, No.1, 369-375, 2022. (Summary) A 72-year-old man visited our hospital due to pollakiuria and lower abdominal pain. Urinary cytology was positive, and cystoscopy revealed diffuse edematous nonpapillary tumor. We performed transurethral biopsy, and clinical stage T3 plasmacytoid variant of urothelial carcinoma (PUC) was diagnosed. Although we planned for radical cystectomy, peritoneal dissemination and lung and pelvic lymph node metastases appeared 3 weeks after the initial visit. We also planned for chemotherapy; however, the metastases rapidly progressed, and he died 7 weeks after the biopsy. PUC is rare and shows an aggressive clinical course and poor prognosis. (Tokushima University Institutional Repository) ● Metadata: 117426 (Link to Publication Site) ● Publication site (DOI): 10.1159/000524038 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35529298 ● Search Scopus @ Elsevier (PMID): 35529298 ● Search Scopus @ Elsevier (DOI): 10.1159/000524038 (Tokushima University Institutional Repository: 117426, DOI: 10.1159/000524038, PubMed: 35529298)
22.	Kitahata Kanako, Takayuki Uchida, Taniguchi Runa, Kato Ayano, Kosuke Sugiura, Iori Sakakibara, Oarada Motoko, Tomoya Fukawa, Junsoo Park, Inho Choi and Takeshi Nikawa : Additional effects of simultaneous treatment with C14-Cblin and celastrol on the clinorotation-induced rat L6 myotube atrophy, The Journal of Medical Investigation : JMI, Vol.69, No.1,2, 127-134, 2022. (Summary) Two novel reagents, N-myristoylated Cbl-b inhibitory peptide (C14-Cblin) and celastrol, a quinone methide triterpene, are reported to be effective in preventing myotube atrophy. The combined effects of C14-Cblin and celastrol on rat L6 myotubes atrophy induced by 3D-clinorotation, a simulated microgravity model, was investigated in the present study. We first examined their effects on expression in atrogenes. Increase in MAFbx1/atrogin-1 and MuRF-1 by 3D-clinorotation was significantly suppressed by treatment with C14-Cblin or celastrol, but there was no additive effect of simultaneous treatment. However, celastrol significantly suppressed the upregulation of Cbl-b and HSP70 by 3D-clinorotation. Whereas 3D-clinorotation decreased the protein level of IRS-1 in L6 myotubes, C14-Cblin and celastrol inhibited the degradation of IRS-1. C14-Cblin and celastrol promoted the phosphorylation of FOXO3a even in microgravity condition. Simultaneous administration of C14-Cblin and celastrol had shown little additive effect in reversing the impairment of IGF-1 signaling by 3D-clinorotation. While 3D-clinorotation-induced marked oxidative stress in L6 myotubes, celastrol suppressed 3D-clinorotation-induced ROS production. Finally, the C14-Cblin and celastrol-treated groups were inhibited decrease in L6 myotube diameter and increased the protein content of slow-twitch MyHC cultured under 3D-clinorotation. The simultaneous treatment of C14-Cblin and celastrol additively prevented 3D-clinorotation-induced myotube atrophy than single treatment. J. Med. Invest. 69 : 127-134, February, 2022. (Keyword) Animals / Atrophy / Humans / Muscle Fibers, Skeletal / Pentacyclic Triterpenes / Rats / Rotation (Tokushima University Institutional Repository) ● Metadata: 116937 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.127 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466134 ● Search Scopus @ Elsevier (PMID): 35466134 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.127 (Tokushima University Institutional Repository: 116937, DOI: 10.2152/jmi.69.127, PubMed: 35466134)
23.	Keito Shiozaki, Yasuo Kawanishi, Yutaro Sasaki, Kei Daizumoto, Megumi Tsuda, Kazuyoshi Izumi, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiroomi Kanayama : Clinical application of virtual imaging guided Robot-assisted partial nephrectomy., The Journal of Medical Investigation : JMI, Vol.69, No.3.4, 237-243, 2022. (Summary) Objectives : To evaluate whether virtual partial nephrectomy images could help surgeons identify vascular and collecting system around tumors during actual surgery. Materials & methods : We retrospectively analyzed 36 patients who underwent robot-assisted partial nephrectomy (RAPN) between 2016 and 2017. Virtual partial nephrectomy images were created from preoperative CT images using computer software, and then analyzed. For analysis, blood vessels and collecting system portions within a 5-mm-thick safety margin around the tumor were examined. During analysis, we predicted whether targeted vasculature around the tumor would require clipping or suturing during surgery, and also whether the collecting system would require opening during resection. Surgical outcomes for virtual partial nephrectomy analyses and actual RAPNs were compared and analyzed for sensitivity and specificity. Results : In 36 cases, 119 arteries and 100 veins were targeted on virtual partial nephrectomy images. Arterial suturing or clipping for hemostasis showed a sensitivity and specificity of 83.3% and 84.5%, respectively. For veins, the sensitivity and specificity were 39.1% and 92.2%, respectively. Collecting system opening prediction sensitivity was 85.7%, and specificity was 65.2%. Conclusion : Virtual partial nephrectomy imaging is useful for RAPN planning, particularly regarding arteries and the collecting system. It is hoped that techniques for visualizing veins will improve. J. Med. Invest. 69 : 237-243, August, 2022. (Keyword) Humans / Kidney Neoplasms / Nephrectomy / Retrospective Studies / Robotic Surgical Procedures / Robotics / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.237 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36244775 ● Search Scopus @ Elsevier (PMID): 36244775 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.237 (DOI: 10.2152/jmi.69.237, PubMed: 36244775)
24.	Madoka Kohno, ANAYT ULLA, Rina Taniguchi, Akane Ohishi, Kako Hirayama, Yuma Takemura, Shoichiro Takao, Yuki Kanazawa, Yuki Matsumoto, Masafumi Harada, Tomoya Fukawa, Hiro-omi Kanayama, Takayuki Uchida, Toshio Suzuki and Takeshi Nikawa : Daily Dietary Supplementation with Steamed Soybean Improves Muscle Volume and Strength in Healthy People Lacking Exercise., Journal of Nutritional Science and Vitaminology, Vol.68, No.6, 521-526, 2022. (Summary) Various dietary protein supplements are used by the elderly and bedridden to maintain their skeletal muscle mass and functions. High-quality proteins act as an anabolic driver and help to improve muscle strength and performance. Previously, we reported that soy protein significantly attenuates denervation-induced loss of muscle mass and myofiber cross sectional area in mice with inhibition of ubiquitination and degradation of IRS-1 in tibialis anterior muscle. It also increased muscle volume and strength in bedridden patients. In the present study, we investigated the effects of dietary soybean supplementation on muscle functions in taxi drivers lacking vigorous physical exercise. We conducted a case-control study on 25 healthy, male taxi drivers between the ages of 36 and 71 y performing minimal physical exercise. They were divided into two dietary groups: the soybean diet group (n=13) who ate daily meals (dinner) supplemented with 50 g of steamed soybean for 30 d and the control diet group (n=12) who received no soybean supplement. Next, we measured the muscle cross-sectional area (CSA) and muscle strength and function in both the groups before and after 30 d of soybean intake. The body weights of both diet groups did not differ significantly over time. However, after 30 d of soybean supplementation, the soybean-fed group developed significantly higher muscle CSA and grip strength compared to the control groups. In conclusion, dietary soybean supplementation improved muscle function in taxi drivers who lacked exercise. (Keyword) Male / Animals / Mice / Soybeans / Case-Control Studies / Muscle, Skeletal / Dietary Supplements / Muscle Strength / Dietary Proteins (Link to Publication Site) ● Publication site (DOI): 10.3177/jnsv.68.521 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36596550 ● Search Scopus @ Elsevier (PMID): 36596550 ● Search Scopus @ Elsevier (DOI): 10.3177/jnsv.68.521 (DOI: 10.3177/jnsv.68.521, PubMed: 36596550)
25.	Kunihisa Yamaguchi, Yutaro Sasaki, Tomoya Fukawa, Masayuki Takahashi and Hiro-omi Kanayama : 腎移植後のリンパ漏にリンパ管造影が効果的であった3例, 日本臨床腎移植学会雑誌, Vol.1, No.19, 118-121, 2021. (Keyword) 腎移植 / リンパ漏 / リンパ管造影 / ジンイショク / リンパロウ / リンパカンゾウエイ (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523388081028360448 (CiNii: 1523388081028360448)
26.	Yutaro Sasaki, 安宅真利花, 多田航生, 中西亮太, 橋本啓佑, 吉岡拓哉, Kei Daizumoto, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hiro-omi Kanayama, Hideya Kashihara and Takuya Tokunaga : Two Cases of Robot-Assisted Total Pelvic Exenteration and Intracorporeal Ileal Conduit for Locally Advanced Rectal Cancer, Acta Urologica Japonica, Vol.68, No.5, 155-159, 2021. (Keyword) Robot-assisted total pelvic exenteration / Intracorporeal urinary diversion / Intracorporeal ileal conduit (Link to Publication Site) ● Publication site (DOI): 10.14989/actauroljap_68_5_155 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390855656035011840 ● Search Scopus @ Elsevier (DOI): 10.14989/actauroljap_68_5_155 (DOI: 10.14989/actauroljap_68_5_155, CiNii: 1390855656035011840)
27.	Yutaro Sasaki, 角陸文哉, 深谷友祐, 山本拓, Kei Daizumoto, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : A Case of Robot-Assisted Radical Cystoprostatectomy for Locally Advanced Prostate Cancer with Bladder Infiltration, Acta Urologica Japonica, Vol.67, No.4, 163-166, 2021. (Summary) While robot-assisted radical cystoprostatectomy (RARC) for locally advanced prostate cancer (LAPC) may sometimes prove to be excessive treatment, it can significantly reduce the risk of positive surgical margins and lower urinary tract obstruction in some cases. Here, we report a case of LAPC treated with RARC in a patient with right hydronephrosis due to bladder infiltration and left hypoplastic kidney. A 71-year-old man presented with frequent urination in August 2019. Prostate-specific antigen (PSA) level was 8.633 ng/ml, and magnetic resonance imaging led to the suspicion that the prostate cancer extended beyond the prostate capsule without distant metastasis. Prostatic biopsy revealed Gleason score 10 (5+5) adenocarcinoma in 8 out of 8 specimens. We diagnosed left hypoplastic kidney and LAPC with right hydronephrosis due to bladder infiltration. We performed percutaneous right nephrostomy and started neoadjuvant hormone therapy. RARC and intracorporeal ileal conduit were performed in March 2020. The prostate was adherent to the anterior surface of the rectum and was difficult to remove. At present, five months after the surgery, the patient remains free of recurrence and metastasis with PSA level <0.003 ng/ml. RARC for LAPC with bladder infiltration can be an effective therapeutic strategy in some cases. (Keyword) Locally advanced prostate cancer / Bladder Invasion / Robot-assisted radical cystoprostatectomy (Link to Publication Site) ● Publication site (DOI): 10.14989/ActaUrolJap_67_4_163 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34107613 ● Summary page in Scopus @ Elsevier: 2-s2.0-85108011497 (DOI: 10.14989/ActaUrolJap_67_4_163, PubMed: 34107613, Elsevier: Scopus)
28.	Yutaro Sasaki, Masayuki Takahashi, Keisuke Ozaki, Kei Daizumoto, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : Efficacy of the direct grasping technique using pean forceps under fluoroscopy to replace ureteral stents in women, The Journal of Medical Investigation : JMI, Vol.3.4, No.68, 326-329, 2021. (Summary) Purpose : To evaluate the efficacy of the direct grasping technique using pean forceps under fluoroscopic guidance for ureteral stent replacement in women. Methods : Between April 2018 and September 2020, 28 female patients underwent ureteral stent replacements at our facility, and 184 stent replacement procedures were performed. A total of 127 stents were replaced using pean forceps under fluoroscopic guidance (pean forceps group), and 57 stents were replaced using the cystoscope (cystoscopy group). Clinical characteristics and surgical outcomes were compared between the groups. Results : All stents were successfully replaced. There was a statistically significant difference in the procedure time between the two groups (median [interquartile range], pean forceps group : 10.8 [8.2-13.9] minutes vs. cystoscopy group : 15.8 [11.1-20.9] minutes, P < 0.001). There were no intraoperative complications in either group and no difference in the incidence of postoperative complications (pean forceps group : 1.6% vs. cystoscopy group : 1.8%, P = 1.000). Fluoroscopy time was longer in the pean forceps group, although this difference was not statistically significant (pean forceps group : 38.9 [22.6-60.1] seconds vs. cystoscopy group : 33.0 [20.0-48.9] seconds, P = 0.0558). Conclusion : The direct grasping technique using pean forceps under fluoroscopy may be a beneficial alternative to cystoscopy for ureteral stent replacement in women. J. Med. Invest. 68 : 326-329, August, 2021. (Keyword) female / Fluoroscopy / Humans / Stents / Surgical Instruments / Ureter / Ureteral Obstruction (Tokushima University Institutional Repository) ● Metadata: 116511 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.326 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759153 ● Search Scopus @ Elsevier (PMID): 34759153 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.326 (Tokushima University Institutional Repository: 116511, DOI: 10.2152/jmi.68.326, PubMed: 34759153)
29.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Tetsuhiro Yano, Kei Daizumoto, Yutaro Sasaki, Keisuke Ozaki, Yoshiteru Ueno, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : [A Case of Pelvic Organ Prolapse and Bladder Diverticulum Surgically Treated at the Same Time]., Acta Urologica Japonica, Vol.66, No.8, 269-272, 2020. (Summary) We report a case of bladder diverticulum presumably caused by lower urinary tract dysfunction due to pelvic organ prolapse (POP) simultaneously treated with transurethral coagulation (TUC) of the bladder diverticulum and laparoscopic sacrocolpopexy (LSC). A literature search showed this is the first report of bladder diverticulum and POP surgically treated at the same time. A 71-year-old woman was referred to our hospital for the treatment of cystocele. She had both storage and voiding symptoms. She had a POPQ stage III cystocele and stage I uterine prolapse. Ultrasonography and computed tomographic scan showed a large volume of residual urine along with a bladder diverticulum. Since urodynamic studies revealed a low compliance bladder and obstruction, we opined that the lower urinary tract symptoms were induced by the cystocele. TUC of the bladder diverticulum and LSC were performed at the same time. After the operation, clean intermittent catheterization (CIC) was needed once a day for one month. Gradually, residual urine decreased and CIC became unnecessary. The bladder diverticulum disappeared, and there has been no recurrence of POP. (Keyword) Aged / Diverticulum / female / Humans / Lower Urinary Tract Symptoms / Pelvic Organ Prolapse / Urinary Bladder / Urinary Bladder, Overactive (Link to Publication Site) ● Publication site (DOI): 10.14989/ActaUrolJap_66_8_269 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32882124 ● Summary page in Scopus @ Elsevier: 2-s2.0-85090318500 (DOI: 10.14989/ActaUrolJap_66_8_269, PubMed: 32882124, Elsevier: Scopus)
30.	Yoshito Kusuhara, Kei Daizumoto, Kaichi Kawai, Kento Hirayama, Minoru Kowada, Terumichi Shintani, Yayoi Fukuhara, Tsogt-Ochir Dondoo, Keisuke Ozaki, Megumi Tsuda, Tomoya Fukawa, Hiroyoshi Nakatsuji, Yoshimi Bando, Hisanori Uehara, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Low Expression of Toll-like Receptor 4 Is Associated With Poor Prognosis in Bladder Cancer., Anticancer Research, Vol.39, No.2, 703-711, 2019. (Summary) Low TLR4 expression was correlated with tumor progression. (Keyword) Aged / Biomarkers, Tumor / Cell Differentiation / Cell Line, Tumor / Computational Biology / Disease Progression / Female / Gene Expression Profiling / Gene Expression Regulation, Neoplastic / Humans / Immunohistochemistry / Male / Middle Aged / Neoplasm Invasiveness / Oligonucleotide Array Sequence Analysis / Prognosis / RNA, Small Interfering / Toll-Like Receptor 4 / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.13166 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30711948 ● Search Scopus @ Elsevier (PMID): 30711948 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.13166 (DOI: 10.21873/anticanres.13166, PubMed: 30711948)
31.	Tomoya Fukawa and Hiro-omi Kanayama : Current knowledge of risk factors for testicular germ cell tumors., International Journal of Urology, Vol.25, No.4, 337-344, 2018. (Summary) The development of the human gonads is tightly regulated by the correct sequential expression of many genes and hormonal activity. Disturbance of this regulation does not only prevent proper development of the gonads, but it also contributes to the development of testicular germ cell tumors. Recent genetic studies, especially genome-wide association studies, have made great progress in understanding genetic susceptibility. Although there is strong evidence of inherited risks, many environmental factors also contribute to the development of testicular germ cell tumors. Histopathological studies have shown that most testicular germ cell tumors arise from germ cell neoplasia in situ, which is thought to be arrested and transformed primordial germ cells. Seminoma has features identical to germ cell neoplasia in situ or primordial germ cells, whereas non-seminoma shows varied differentiation. Seminomas and embryonic cell carcinomas have the feature of pluripotency, which is thought to be the cause of histological heterogeneity and mixed pathology in testicular germ cell tumors. Testicular germ cell tumors show high sensitivity to chemotherapies, but 20-30% of patients show resistance to standard chemotherapy. In the present review, the current knowledge of the epidemiological and genomic factors for the development of testicular germ cell tumors is reviewed, and the mechanisms of resistance to chemotherapies are briefly mentioned. (Keyword) oncology / Testicular tumor (Link to Publication Site) ● Publication site (DOI): 10.1111/iju.13519 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29345008 ● Search Scopus @ Elsevier (PMID): 29345008 ● Search Scopus @ Elsevier (DOI): 10.1111/iju.13519 (DOI: 10.1111/iju.13519, PubMed: 29345008)
32.	Kei Daizumoto, Tetsuro Yoshimaru, Yosuke Matsushita, Tomoya Fukawa, Hisanori Uehara, Masaya Ono, Masato Komatsu, Hiro-omi Kanayama and Toyomasa Katagiri : A DDX31/mutant-p53/EGFR axis promotes multistep progression of muscle invasive bladder cancer, Cancer Research, Vol.78, No.9, 2233-2247, 2018. (Summary) The p53 and EGFR pathways are frequently altered in bladder cancer, yet their contributions to its progression remain elusive. Here we report that DEAD box polypeptide 31 (DDX31) plays a critical role in the multistep progression of muscle-invasive bladder cancer (MIBC) through its sequential interactions with mutant p53 (mutp53) and EGFR. In early MIBC cells, nuclear DDX31-bound mutp53/SP1 enhanced mutp53 transcriptional activation, leading to migration and invasion of MIBC. Cytoplasmic DDX31 also bound EGFR and phospho-nucleolin in advanced MIBC, leading to EGFR-Akt signaling activation. High expression of both cytoplasmic DDX31 and p53 proteins correlated with poor prognosis in patients with MIBC, and blocking the DDX31/NCL interaction resulted in downregulation of EGFR/Akt signaling, eliciting an antitumor effect against bladder cancer. These findings reveal that DDX31 cooperates with mutp53 and EGFR to promote progression of MIBC, and inhibition of DDX31/NCL formation may lead to potential treatment strategies for advanced MIBC. DDX31 cooperates with mutp53 and EGFR to promote progression of muscle invasive bladder cancer. . (Tokushima University Institutional Repository) ● Metadata: 111804 (Link to Publication Site) ● Publication site (DOI): 10.1158/0008-5472.CAN-17-2528 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29440146 ● Search Scopus @ Elsevier (PMID): 29440146 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-17-2528 (Tokushima University Institutional Repository: 111804, DOI: 10.1158/0008-5472.CAN-17-2528, PubMed: 29440146)
33.	Hidehisa Mori, Tomoharu Fukumori, KEI DAIZUMOTO, MEGUMI TSUDA, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiro-omi Kanayama : Predictive Factors for Prolonged Urination Disorder After Permanent 125I Brachytherapy for Localized Prostate Cancer, In Vivo, Vol.31, No.4, 755-761, 2017. (Summary) We assessed the change in LUTS after prostate brachytherapy to reveal factors for prolonged urination disorder. Four hundred and four patients received prostate brachytherapy at our institution and were followed-up for at least 2 years. We evaluated the correlation of mean IPSS changes and clinical factors. Using multivariate analysis, we also evaluated clinical factors with potential to delay IPSS resolution. In cases with prostate volume more than 30 cm, radiation dose to 90% of prostate volume (D90) more than 160 Gy, and radiation dose to 30% of the urethral volume (UD30) more than 240 Gy, mean IPSS levels were significantly higher, even 30 months after treatment. On multivariate analysis, baseline IPSS more than 8 points and D90 more than 160 Gy were significant predictors for delayed IPSS resolution. Our data suggest that higher baseline IPSS and higher D90 were predictors for prolonged urination disorder. (Keyword) Aged / Aged, 80 and over / Brachytherapy / Humans / Iodine Radioisotopes / male / Middle Aged / Prostate / Prostate-Specific Antigen / Prostatic Neoplasms / Urination Disorders (Tokushima University Institutional Repository) ● Metadata: 113626 (Link to Publication Site) ● Publication site (DOI): 10.21873/invivo.11127 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28652453 ● Summary page in Scopus @ Elsevier: 2-s2.0-85028539877 (Tokushima University Institutional Repository: 113626, DOI: 10.21873/invivo.11127, PubMed: 28652453, Elsevier: Scopus)
34.	Terumichi Shintani, Yoshito Kusuhara, Kei Daizumoto, Tsogt-Ochir Dondoo, Yasuyo Yamamoto, Hidehisa Mori, Tomoya Fukawa, Hiroyoshi Nakatsuji, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : The Involvement of Hepatocyte Growth Factor-MET-Matrix Metalloproteinase 1 Signaling in Bladder Cancer Invasiveness and Proliferation. Effect of the MET Inhibitor, Cabozantinib (XL184), on Bladder Cancer Cells., Urology, Vol.101, 169.e7-169.e13, 2017. (Summary) To clarify the invasive mechanisms of muscle-invasive bladder cancer (BCa) would be useful for the determination of appropriate treatment strategies. We previously showed that hepatocyte growth factor (HGF)-MET signaling is correlated with invasiveness of BCa cells. Here, we investigated the effects of the MET inhibitor, cabozantinib (XL184), on BCa cells. We first conducted Western blot analysis to investigate MET expression in BCa cell lines. Next, we examined the effect of cabozantinib on their proliferation and invasive abilities using MTT and Matrigel invasion assays, respectively. Invasion assays were performed using the xCELLigence system. Additionally, to investigate the biological function of HGF-MET signaling, we analyzed gene expression profiles and performed real-time polymerase chain reaction analyses of 5637 cells that were cultivated with or without HGF stimulation, with or without cabozantinib. MET was highly expressed in 4 of 5 BCa cell lines, and 5637 and T24 cells showed especially high protein expression of MET. Cabozantinib suppressed cell proliferation and invasion (cell index; mock, 1.49 vs HGF, 2.26 vs HGF + XL184, 1.47, P < .05). Gene expression profile analysis indicated that matrix metalloproteinase 1 (MMP1) was significantly elevated at the mRNA level with addition of HGF. Moreover, cabozantinib suppressed HGF-induced MMP1 expression in 5637 T24 cells. These data indicate that cabozantinib suppressed MMP1 expression by blocking HGF-MET signaling and that HGF-MET-MMP1 signaling is involved in the invasiveness and proliferation of BCa cells. These results suggest that cabozantinib might prove useful for future treatment of muscle-invasive BCa. (Keyword) Anilides / Blotting, Western / Cell Count / Cell Line, Tumor / Cell Proliferation / Gene Expression Regulation, Neoplastic / Hepatocyte Growth Factor / Humans / Matrix Metalloproteinase 1 / Neoplasm Invasiveness / Protein Array Analysis / Proto-Oncogene Proteins c-met / Pyridines / RNA, Neoplasm / Receptor Protein-Tyrosine Kinases / Reverse Transcriptase Polymerase Chain Reaction / signal transduction / Urinary Bladder / Urinary Bladder Neoplasms (Tokushima University Institutional Repository) ● Metadata: 110112 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.urology.2016.12.006 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28013036 ● Summary page in Scopus @ Elsevier: 2-s2.0-85009932260 (Tokushima University Institutional Repository: 110112, DOI: 10.1016/j.urology.2016.12.006, PubMed: 28013036, Elsevier: Scopus)
35.	Tomokazu Senzaki, Tomoharu Fukumori, Hidehisa Mori, Yoshito Kusuhara, Masatsugu Komori, Junichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Akiko Kubo, Takashi Kawanaka, Shunsuke Furutani, Hitoshi Ikushima and Hiro-omi Kanayama : Clinical Significance of Neoadjuvant Combined Androgen Blockade for More Than Six Months in Patients with Localized Prostate Cancer Treated with Prostate Brachytherapy., Urologia Internationalis, Vol.95, No.4, 457-464, 2015. (Summary) The aim of this study is to clarify the clinical significance of neoadjuvant combined androgen blockade (CAB) for ≥ 6 months in patients with localized prostate cancer. A total of 431 patients with localized prostate cancer who underwent prostate brachytherapy (BT) with or without neoadjuvant CAB for ≥ 6 months with mean follow-up time of 64.6 months (range 24-108 months) were evaluated retrospectively. Of those 431, 232 patients received BT in combination with neoadjuvant CAB for ≥ 6 months. Biochemical recurrence-free rates (BRFRs) in 364 patients with at least 3 years of follow-up were evaluated by log-rank test. BRFR in patients with low-, intermediate- and high-risk prostate cancer were 98.1, 94.2 and 89.1%, respectively. In patients with intermediate-risk prostate cancer only, neoadjuvant CAB was significantly associated with BRFR (p = 0.0468). Especially in patients with intermediate-risk prostate cancer with radiation dose received by 90% of the prostate (D90) < 180 Gy, neoadjuvant CAB exerted a favorable impact on BRFR (p = 0.0429). On multivariate analyses, neoadjuvant CAB and D90 were independent predictors of BRFR (p = 0.0061 and p < 0.0001, respectively). Neoadjuvant CAB for ≥ 6 months has a favorable impact on BRFR in patients with intermediate-risk prostate cancer, particularly in patients with relatively low radiation doses of D90. (Link to Publication Site) ● Publication site (DOI): 10.1159/000439573 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26461847 ● Search Scopus @ Elsevier (PMID): 26461847 ● Search Scopus @ Elsevier (DOI): 10.1159/000439573 (DOI: 10.1159/000439573, PubMed: 26461847)
36.	小居浩之, 大豆本圭, Yasuyo Yamamoto, Jun-ichiro Kagawa, Masatsugu Komori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Hirofumi Izaki : RETROPERITONEAL SCHWANNOMA WITH INCREASED F18-FLUORODEOXYGLUCOSE UPTAKE ON POSITRON EMISSION TOMOGRAPHY : A CASE REPORT, The Nishinihon Journal of Urology, Vol.77, No.8, 297-301, 2015. (Keyword) 後腹膜神経鞘腫 / ¹⁸F-FDGPET-CT / retroperitoneal schwannoma (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853833143993344 ● Summary page in Scopus @ Elsevier: 2-s2.0-84941121427 (CiNii: 1520853833143993344, Elsevier: Scopus)
37.	Masayuki Takahashi, Yoshito Kusuhara, Hidehisa Mori, Masatsugu Komori, Junichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Long-Term Administration of Docetaxel Over 70 Cycles for Castration-Resistant Prostate Cancer., Clinical Genitourinary Cancer, Vol.13, No.4, e337-40, 2015. (Keyword) Aged / Antineoplastic Agents / Bone Neoplasms / Drug Administration Schedule / Fatal Outcome / Humans / Maintenance Chemotherapy / Male / Middle Aged / Prostatic Neoplasms, Castration-Resistant / Taxoids (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clgc.2015.01.012 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 25770768 ● Summary page in Scopus @ Elsevier: 2-s2.0-84936985299 (DOI: 10.1016/j.clgc.2015.01.012, PubMed: 25770768, Elsevier: Scopus)
38.	佐々木雄太郎, 小居浩之, 大山拓郎, Jun-ichiro Kagawa, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Hisaya Takahashi, Masahiko Takemura, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : NON-MUSCLE INVASIVE BLADDER CANCER WITH MULTIPLE BONE METASTASIS WITHOUT LOCAL INVASION : A CASE REPORT, Acta Urologica Japonica, Vol.59, No.10, 669-672, 2013. (Summary) A 66-year-old man with superficial bladder cancer was treated with transurethral resection (TURBT) in October 2011. The pathological diagnosis was urothelial carcinoma (UC), grade 2, T1. A second TURBT was performed one month later. The pathological diagnosis was UC, grade 3, T1. He was treated with intravesical bacillus Calmette-Guerin (BCG) after TURBT. His progress was satisfactory, but a small superficial bladder cancer was found on cystoscopy in August 2012. He was going to be treated with TURBT, but the serum alkaline phosphatase level was abnormally high on preoperative evaluation. Bone scintigraphy showed multiple bone metastases from non-muscle invasive bladder cancer (NMIBC) without local invasion. He was started on combined chemotherapy with 1,000 mg/m2 gemcitabine on days 1, 8 and 15 and 70 mg/m2 cisplatin on day 2 every four weeks. He received denosumab for multiple bone metastases at the same time. Although he subsequently developed severe hypocalcemia, treatment was continued, and he completed four courses of chemotherapy. Bone scintigraphy and contrast-enhanced computed tomography showed reduction of the multiple bone metastases, and alkaline phosphatase decreased to the normal range. It is rare for NMIBC without local invasion to metastasize to other organs. Thus, it is necessary to consider distant metastases in patients with NMIBC. (Keyword) Non-muscle invasive / Bladder cancer / Bone metastasis (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24262709 ● CiNii @ National Institute of Informatics (CRID): 1050845760708113920 ● Summary page in Scopus @ Elsevier: 2-s2.0-84888314282 (PubMed: 24262709, CiNii: 1050845760708113920, Elsevier: Scopus)
39.	Masayuki Takahashi, Masatsugu Komori, Jun-ichiro Kagawa, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Hisaya Takahashi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 小児低形成腎/機能低下腎に対する腹腔鏡下腎摘除術の臨床的検討, Japanese Journal of Endourology, Vol.26, No.2, 263-269, 2013. (Summary) We reviewed the results of laparoscopic nephrectomy for children with a hypoplastic or poorly functioning kidney in our department. Laparoscopic nephrectomy was performed in 10 patients including 1 boy and 9 girls. The patients' median age was 5.5 years old. There were 8 patients with a hypoplastic kidney and an ectopic ureter, and 2 patients with a poorly functioning kidney and a megaureter or vesicoureteral reflux. Laparoscopic nephrectomy was conducted transperitoneally in 5 and retroperitoneally in 5 patients. The median operative time was 167 minutes. There was no intraoperative complication. Postoperatively, subcutaneous emphysema and fever developed in one patient each. 7 patients used an analgesic suppository once or several times, and 3 patients received no analgesics. Oral intake was started at a median of 1 day postoperatively. The median hospital stay after surgery was 4.5 days. Laparoscopic nephrectomy for a hypoplastic and poorly functioning kidney in children is a minimally invasive surgery. (Keyword) 小児 / 鏡視下腎摘除術 / 尿管異所開口 (Link to Publication Site) ● Publication site (DOI): 10.11302/jsejje.26.263 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205509695360 ● Search Scopus @ Elsevier (DOI): 10.11302/jsejje.26.263 (DOI: 10.11302/jsejje.26.263, CiNii: 1390001205509695360)
40.	Masayuki Takahashi, Kawabata Rumi, Kawano Akira, Murakami Yoshihide, Sutou Yasushi, Inai Tohru, Akazawa Seiji, Hamao Takumi, Hayashi Hideki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : Substitution of antiandrogens and tegafur-uracil combination therapy for castration-resistant prostate cancer: results of a multi-center randomized phase II study, International Journal of Oncology, Vol.43, No.3, 713-720, 2013. (Summary) We conducted this study to determine whether substitution with anti-androgen (SOA) and tegafur-uracil (a pro-drug of 5-FU) combination therapy is more effective than SOA alone after relapse from initial hormonal therapy. Patients who were histologically confirmed and relapsed after initial hormonal therapy were included. All patients were randomly allocated into two groups: SOA alone (group A) or SOA combined with tegafur-uracil (group B). The mRNA expression of four enzymes, including thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), orotate phospho-ribosyltransferase (OPRT) and thymidine phosphorylase (TP), in prostate cancer cells was analyzed by quantitative reverse-transcription polymerase chain reaction. Fifty-two patients were enrolled in this study. The median age was 77 (range: 47-92) years. The PSA response rate in group B (61.5%) tended to be higher compared to that in group A (34.6%) (p=0.095). Group B (median: 15.9 months) had a significantly longer time to PSA progression (TTP) compared to group A (6.4 months) (p=0.014). In patients with a lower TS expression or a higher OPRT expression, group B demonstrated a higher PSA response rate compared to group A (p=0.019 and p=0.041, respectively). In addition, in the patients with a lower TS expression, group B demonstrated a significantly longer TTP compared to group A (p=0.018). There were no severe adverse events in either treatment group. After relapse from initial hormonal therapy, SOA combined with tegafur-uracil is effective and well tolerated. The TS mRNA expression level may be a predictive factor for this combination therapy. (Keyword) Aged / Aged, 80 and over / Androgen Antagonists / Antineoplastic Combined Chemotherapy Protocols / Dihydrouracil Dehydrogenase (NADP) / Gene Expression Regulation, Neoplastic / Humans / Male / Middle Aged / Orotate Phosphoribosyltransferase / Prostatic Neoplasms, Castration-Resistant / RNA, Messenger / Tegafur / Thymidine Phosphorylase / Thymidylate Synthase / Uracil (Link to Publication Site) ● Publication site (DOI): 10.3892/ijo.2013.1997 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23817692 ● Summary page in Scopus @ Elsevier: 2-s2.0-84880578556 (DOI: 10.3892/ijo.2013.1997, PubMed: 23817692, Elsevier: Scopus)
41.	Hisaya Takahashi, Yasuyo Yamamoto, 小居浩之, 大山拓郎, 佐々木雄太郎, Masatsugu Komori, Jun-ichiro Kagawa, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : CLINICAL EXPERIENCE OF INTERSTITIAL CYSTITIS TREATED WITH HYDRODISTENSION, The Nishinihon Journal of Urology, Vol.75, No.8, 413-417, 2013. (Keyword) 間質性膀胱炎 / 水圧拡張術 / interstitial cystitis (IC) hydrodistension (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520290882119498752 ● Summary page in Scopus @ Elsevier: 2-s2.0-84884299458 (CiNii: 1520290882119498752, Elsevier: Scopus)
42.	Kojiro Nagai, Masashi Miyoshi, Takei Kake, Naoshi Fukushima, Motokazu Matsuura, Eriko Shibata, Satoshi Yamada, Kazuhiro Yoshikawa, Hiro-omi Kanayama, Tomoya Fukawa, Kunihisa Yamaguchi, Hirofumi Izaki, Akira Mima, Naoko Abe, Toshikazu Araoka, Taichi Murakami, Fumi Kishi, Seiji Kishi, Tatsuya Tominaga, Tatsumi Moriya, Hideharu Abe and Toshio Doi : Dual Involvement of Growth Arrest-specific Gene 6 in the Early Phase of Human IgA Nephropathy, PLoS ONE, Vol.8, No.6, e66759, 2013. (Summary) Gas6 is a growth factor that causes proliferation of mesangial cells in the development of glomerulonephritis. Gas6 can bind to three kinds of receptors; Axl, Dtk, and Mer. However, their expression and functions are not entirely clear in the different glomerular cell types. Meanwhile, representative cell cycle regulatory protein p27 has been reported to be expressed in podocytes in normal glomeruli with decreased expression in proliferating glomeruli, which inversely correlated with mesangial proliferation in human IgA nephropathy (IgAN). The aim of this study is to clarify Gas6 involvement in the progression of IgAN. Expression of Gas6/Axl/Dtk was examined in 31 biopsy proven IgAN cases. We compared the expression levels with histological severity or clinical data. Moreover, we investigated the expression of Gas6 and its receptors in cultured podocytes. In 28 of 31 cases, Gas6 was upregulated mainly in podocytes. In the other 3 cases, Gas6 expression was induced in endothelial and mesangial cells, which was similar to animal nephritis models. Among 28 podocyte type cases, the expression level of Gas6 correlated with the mesangial hypercellularity score of IgAN Oxford classification and urine protein excretion. It also inversely correlated with p27 expression in glomeruli. As for the receptors, Axl was mainly expressed in endothelial and mesangial cells, while Dtk was expressed in podocytes. In vitro, Dtk was expressed in cultured murine podocytes, and the expression of p27 was decreased by Gas6 stimulation. Gas6 was uniquely upregulated in either endothelial/mesangial cells or podocytes in IgAN. The expression pattern can be used as a marker to classify IgAN. Gas6 has a possibility to be involved in not only mesangial proliferation via Axl, but also podocyte injury via Dtk in IgAN. (Keyword) Cells, Cultured / Endothelial Cells / Glomerulonephritis, IGA / Humans / Immunohistochemistry / Intercellular Signaling Peptides and Proteins / Mesangial Cells / Podocytes (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0066759 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23826128 ● Summary page in Scopus @ Elsevier: 2-s2.0-84879474790 (DOI: 10.1371/journal.pone.0066759, PubMed: 23826128, Elsevier: Scopus)
43.	Tomoteru Kishimoto, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : Mineralocorticoid receptor expression in human penile corpus cavernosum, The Journal of Medical Investigation : JMI, Vol.60, 21-26, 2013. (Summary) Mineralocorticoid receptor (MR) is known to play physiological and pathophysiological roles in the cardiovascular system, and MR activation directly damages these organs. The aim of this study was to evaluate the expression of MR and 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) in the human penile corpus cavernosum. MR and 11β-HSD2 expression was assayed in human penile tissues, and also in human renal tissues as a positive control. Expressions of MR mRNA and 11β-HSD2 mRNA were evaluated using reverse transcription polymerase chain reaction (RT-PCR). MR and 11β-HSD2 were visually identified using immunofluorescence analysis. MR mRNA expression in human penis was confirmed by RT-PCR. On quantitative RT-PCR analysis, 11β-HSD2 mRNA expression was detected at minimal levels in penile tissue. Immunofluorescence analysis revealed positive staining for MR and negative staining for 11β-HSD2 in smooth muscle cells of the corpus cavernosum. This study demonstrated the presence of MR and the absence of 11β-HSD2 in human penile corpus cavernosum. Considering that MR activation causes various organ damages, MR blockade in human penile corpus cavernosum may have therapeutic benefits. Investigations for the penile effects of MR activation have the potential to provide new treatment approaches for erectile dysfunction. (Keyword) 11-beta-Hydroxysteroid Dehydrogenase Type 2 / Adult / Aged / Erectile Dysfunction / Fluorescent Antibody Technique / Humans / Male / Middle Aged / Mineralocorticoid Receptor Antagonists / Penis / RNA, Messenger / Receptors, Mineralocorticoid (Tokushima University Institutional Repository) ● Metadata: 106037 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.60.21 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23614907 ● Summary page in Scopus @ Elsevier: 2-s2.0-84876057957 (Tokushima University Institutional Repository: 106037, DOI: 10.2152/jmi.60.21, PubMed: 23614907, Elsevier: Scopus)
44.	Hisaya Takahashi, 津田恵, 大豆本圭, 三宅毅志, 塩﨑啓登, Masatsugu Komori, Jun-ichiro Kagawa, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : CLINICAL EXPERIENCE OF REITER'S SYNDROME FOLLOWING BCG INTRAVESICAL THERAPY, The Nishinihon Journal of Urology, Vol.76, 10-14, 2013. (Keyword) Reiter症候群 / BCG膀胱内注入療法 / 膀胱癌 / Reiter's syndrome / intravesical BCG therapy / bladder cancer (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520853832090604416 ● Summary page in Scopus @ Elsevier: 2-s2.0-84894647903 (CiNii: 1520853832090604416, Elsevier: Scopus)
45.	Tomoya Fukawa, Masaya Ono, Taisuke Matsuo, Hisanori Uehara, Tsuneharu Miki, Yusuke Nakamura, Hiro-omi Kanayama and Toyomasa Katagiri : DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas, Cancer Research, Vol.72, No.22, 5867-5877, 2012. (Summary) Studies of renal cell carcinoma (RCC) have led to the development of new molecular-targeted drugs but its oncogenic origins remain poorly understood. Here, we report the identification and critical roles in renal carcinogenesis for DDX31, a novel nucleolar protein upregulated in the vast majority of human RCC. Immunohistochemical overexpression of DDX31 was an independent prognostic factor for patients with RCC. RNA interference (RNAi)-mediated attenuation of DDX31 in RCC cells significantly suppressed outgrowth, whereas ectopic DDX31 overexpression in human 293 kidney cells drove their proliferation. Endogenous DDX31 interacted and colocalized with nucleophosmin (NPM1) in the nucleoli of RCC cells, and attenuation of DDX31 or NPM1 expression decreased pre-ribosomal RNA biogenesis. Notably, in DDX31-attenuated cells, NPM1 was translocated from nucleoli to the nucleoplasm or cytoplasm where it bound to HDM2. As a result, HDM2 binding to p53 was reduced, causing p53 stablization with concomitant G(1) phase cell-cycle arrest and apoptosis. Taken together, our findings define a mechanism through which control of the DDX31-NPM1 complex is likely to play critical roles in renal carcinogenesis. (Keyword) Animals / COS Cells / Carcinoma, Renal Cell / Cell Nucleolus / DEAD-box RNA Helicases / HEK293 Cells / Humans / immunohistochemistry / Kidney Neoplasms / Nuclear Proteins / Prognosis / Proto-Oncogene Proteins c-mdm2 / RNA, Ribosomal / signal transduction / Transcription, Genetic / Transfection / Tumor Suppressor Protein p53 / Up-Regulation (Link to Publication Site) ● Publication site (DOI): 10.1158/0008-5472.CAN-12-1645 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23019224 ● Search Scopus @ Elsevier (PMID): 23019224 ● Search Scopus @ Elsevier (DOI): 10.1158/0008-5472.CAN-12-1645 (DOI: 10.1158/0008-5472.CAN-12-1645, PubMed: 23019224)
46.	Takuya Tsujioka, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : BCG膀胱内注入療法後に発症した結核性精巣上体炎の1例, 泌尿器外科, Vol.25, No.11, 2217-2220, 2012.
47.	Masayuki Takahashi, Kosuke Seto, Takuya Tsujioka, Ryotaro Tomita, Megumi Tsuda, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : SEQUENTIAL THERAPY WITH MOLECULAR TARGETED AGENTS FOR ADVANCED RENAL CELL CARCINOMA, The Nishinihon Journal of Urology, Vol.74, No.5, 258-263, 2012. (Keyword) renal cell carcinoma / molecular targeted agent / sequential therapy (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520572357422341632 ● Summary page in Scopus @ Elsevier: 2-s2.0-84861809136 (CiNii: 1520572357422341632, Elsevier: Scopus)
48.	Hisaya Takahashi, Hiroyoshi Nakatsuji, Masayuki Takahashi, Avirmed Shiirevnyamba, Tomoya Fukawa, Masahiko Takemura, Tomoharu Fukumori and Hiro-omi Kanayama : Up-regulation of Plakophilin-2 and Down-regulation of Plakophilin-3 are Correlated With Invasiveness in Bladder Cancer, Urology, Vol.79, No.1, 240e1-240e8, 2012. (Summary) To examine plakophilin proteins (Pkp) and 3 expression levels in bladder cancer, in particular their levels during cellular growth and invasion. Pkp is associated with the binding of cadherin to intermediate filaments of the cytoskeleton. The relative mRNA and protein expression levels of Pkp2 and 3 in bladder cancer cell lines were determined using quantitative real-time polymerase chain reaction and Western blot analyses. The cellular localization of Pkp2 and 3 proteins in bladder cancer cells was also assayed using immunohistochemistry. The proliferation and invasive activities of bladder cancer cells were evaluated using cell growth and in vitro cell invasion assays, and were compared with those of bladder cancer cells treated with Pkp2 and 3 small interfering RNAs. Pkp2 mRNA and protein levels were elevated, and those of Pkp3 were reduced, in bladder cancer cells that are known to exhibit increased proliferation and invasive activity. Pkp2/3 protein expression was predominantly observed in the cytoplasm of invasive bladder cancer cells and tissues. Pkp2 knockdown inhibited, and Pkp3 knockdown enhanced, invasion of bladder cancer cells, but these knockdowns did not alter cell proliferation. We conclude that high Pkp2, and low Pkp3, expression is associated with bladder cancer cell invasion and that neither Pkp2 nor Pkp3 is associated with cell proliferation. We further hypothesize that accumulation of Pkp2 and 3 in the cell cytoplasm, rather than their recruitment to the cell membrane, is related to an increased ability of the tumor to invade and metastasize. (Keyword) Blotting, Western / Cell Line, Tumor / Cell Proliferation / Down-Regulation / Gene Expression Regulation, Neoplastic / Humans / Immunohistochemistry / Microscopy, Fluorescence / Neoplasm Invasiveness / Plakophilins / RNA, Messenger / Real-Time Polymerase Chain Reaction / Sensitivity and Specificity / Up-Regulation / Urinary Bladder Neoplasms (Tokushima University Institutional Repository) ● Metadata: 106137 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.urology.2011.08.049 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22119253 ● Search Scopus @ Elsevier (PMID): 22119253 ● Search Scopus @ Elsevier (DOI): 10.1016/j.urology.2011.08.049 (Tokushima University Institutional Repository: 106137, DOI: 10.1016/j.urology.2011.08.049, PubMed: 22119253)
49.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Shunsuke Furutani, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 中間リスク群，高リスク群前立腺癌に対するI-125密封小線源療法の治療成績, Japanese Journal of Endourology, Vol.24, No.1, 131-135, 2011. (Keyword) prostate cancer / brachytherapy / risk group classification (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205509858560 (CiNii: 1390001205509858560)
50.	Masayuki Takahashi, HIROYUKI YAMAMOTO, AKIHITO YUASA, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : CLINICAL REVIEW OF ELDERLY PATIENTS WITH RENAL TUMORS IN OUR HOSPITAL, The Nishinihon Journal of Urology, Vol.72, No.7, 363-370, 2010. (Summary) 初診時80歳以上の腎腫瘍患者24例(男17例・女7例・中央値81.5歳)の成績を報告した．ECOG performance status(PS)は0:9例，1:7例，2:3例，3:1例，4:3例，不明:1例，臨床病期はstage I:11例，II:2例，III:5例，IV:6例であった．腎摘出術を施行したのは6例で，PSは0:4例，1:1例，2:1例，病期はstage I:4例，II:1例，III:1例であった．非手術の理由は，本人・家族が希望しない，手術適応外，合併症の存在などであった．全生存期間の中央値は25ヵ月で，stage I:44ヵ月，II:10ヵ月，III:9ヵ月，IV:25ヵ月であった．癌特異生存期間の中央値はstage I:44ヵ月，II:10ヵ月，III:15ヵ月，IV:18ヵ月であった．stage I・IIの13例を手術施行5例と非手術8例に分け比較したが，全生存率，癌特異生存率ともに有意差はなかった．また，stage III・IVを治療介入7例と無治療3例に分けて行った比較でも，同様に有意差はなかった． (Keyword) RCC / elderly patients / survival / 腎細胞癌 / 高齢者 / 生存率 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520290883090281344 ● Summary page in Scopus @ Elsevier: 2-s2.0-77955855677 (CiNii: 1520290883090281344, Elsevier: Scopus)

Academic Paper (Unrefereed Paper):

1.	Yutaro Sasaki, 安宅真利花, 多田航生, 中西亮太, 橋本啓佑, 吉岡拓哉, Kei Daizumoto, 尾崎啓介, 上野恵輝, Megumi Tsuda, 楠原義人, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hiro-omi Kanayama, Hideya Kashihara and Takuya Tokunaga : Two Cases of Robot-Assisted Total Pelvic Exenteration and Intracorporeal Ileal Conduit for Locally Advanced Rectal Cancer, Acta Urologica Japonica, Vol.68, No.5, 155-159, 2022. (Summary) We describe two cases of locally advanced rectal cancer (LARC) treated with robot-assisted total pelvic exenteration (Ra-TPE) and intracorporeal ileal conduit (ICIC). The first case was in a 71-year-old man with LARC (RbP, T4bN2bM0, cStage IIIc). He was started on bevacizumab+S-1/oxaliplatin therapy in July 2019. In April 2020, he developed Fournier's gangrene due to subcutaneous penetration of rectal cancer. Emergency drainage and colostomy were performed simultaneously, and a percutaneous vesical fistula was created. In May 2020, Ra-TPE and ICIC were performed. Histopathological analysis revealed moderately differentiated tubular adenocarcinoma (ypT3N0, RM0). At postoperative 9 months, thoracoscopic right upper lobectomy was performed for a right metastatic lung tumor. At present, ie, at postoperative 12 months, the patient has been free of recurrence and metastasis, with a carcinoembryonic antigen (CEA) level of 1.4 ng/ml and carcinoma antigen (CA) 19-9 level of 11 U/ml. The second case was in a 61-year-old man with fistula-associated anal cancer (PRb, T4N3M1b, cStage IVb). In April 2019, he was started on FOLFOXIRI+cetuximab therapy. In August 2020, Ra-TPE, ICIC, and transperineal total mesenteric excision were performed. Histopathological analysis revealed adenocarcinoma (ypT4N0, RM0). At postoperative 11 months, thoracoscopic left lower lobectomy was performed for a left metastatic lung tumor. At present, ie, at postoperative 12 months, the patient remains free of recurrence and metastasis, with a CEA level of 7.3 ng/ml and CA19-9 level of 12 U/ml. Ra-TPE, which allows transperineal removal of a specimen, can be performed as a minimally invasive surgery in combination with ICIC. (Keyword) 腫瘍多剤併用療法骨盤内臓器全摘術生検腺癌(X線診断,病理学,治療) X線CT 直腸腫瘍(X線診断,病理学,治療) 尿路変更術膀胱造瘻術ネオアジュバント療法 Oxaliplatin(治療的利用) TS-1(治療的利用) Bevacizumab(治療的利用) 放射線化学療法結腸造瘻術ロボット手術ヒト中年(45∼64) 高齢者(65∼79) 男 (Link to Publication Site) ● Publication site (DOI): 10.14989/actauroljap_68_5_155 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390855656035011840 ● Summary page in Scopus @ Elsevier: 2-s2.0-85132908756 (DOI: 10.14989/actauroljap_68_5_155, CiNii: 1390855656035011840, Elsevier: Scopus)
2.	Kunihisa Yamaguchi, Yutaro Sasaki, Tomoya Fukawa and Masayuki Takahashi : 腎移植後のリンパ漏にリンパ管造成が効果的であった3例, 日本臨床腎移植学会雑誌, Vol.9, No.1, 118-121, 2021.
3.	井内俊輔, Hidehisa Mori, 大豆本圭, 津田恵, Yoshito Kusuhara, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 徳島大学泌尿器科におけるBCG膀胱内注入療法の臨床検討, 泌尿器外科, Vol.28, No.3, 330-331, 2015.
4.	Masahiko Takemura, Hirofumi Izaki, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 子宮頸癌副腎転移との識別が困難であった18F-FDG PET/CT陽性副腎皮質線種の1例, 泌尿紀要, Vol.59, 91-95, 2013.
5.	Tomoharu Fukumori, Shunsuke Furutani, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 限局性前立腺癌に対する密封小線源療法のリスク分類別治療成績, 泌尿器外科, Vol.27, No.8, 1651-1654, 2012.
6.	Tomoteru Kishimoto, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama and Susumu Kagawa : 射精障害を契機に発見されたトルコ鞍空洞症を伴う汎下垂体機能低下症の1例, The Japanese Journal of Sexual Medicine, Vol.26, No.1, 21-26, 2011. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1572543024868809472 (CiNii: 1572543024868809472)
7.	津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : BCG膀胱内注入療法後に生じたReiter症候群の1例, The Nishinihon Journal of Urology, Vol.73, No.10, 559-561, 2011. (Keyword) *BCGワクチン(治療的利用,毒性・副作用) (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-82055207262 (Elsevier: Scopus)
8.	Tomoharu Fukumori, Takahiro Koizumi, 山本洋之, 湯浅明人, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Training system of laparoscopic surgery for young urologists in the university of Tokushima, The Nishinihon Journal of Urology, Vol.72, No.6, 285-288, 2010. (Keyword) laparoscopic surgery / training / 腎臓摘出術 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520009408512732416 ● Summary page in Scopus @ Elsevier: 2-s2.0-77954345645 (CiNii: 1520009408512732416, Elsevier: Scopus)
9.	Manabu Sakaki, Tomoharu Fukumori, Tomoya Fukawa, Essam Elsamman, Avirmed Shiirevnyamba, Hiroyoshi Nakatsuji and Hiro-omi Kanayama : Clinical significance of Galectin-3 in clear cell renal cell carcinoma., The Journal of Medical Investigation : JMI, Vol.57, No.1-2, 152-157, 2010. (Summary) Overexpression of galectin-3 in a variety of cancer cell lines has been shown to correlate with tumor progression and metastasis. In this study, we investigated the expression of galectin-3 in clear cell renal cell carcinoma (CC-RCC) and evaluated the relationship between galectin-3 expression levels and the clinicopathological features of CC-RCC. Expression of galectin-3 in the kidney cancer cell lines Caki-1, Caki-2, A704, ACHN and KPK-1 were evaluated using western blot analysis, while galectin-3 expression in CC-RCC tissues and normal parenchyma were measured by real-time PCR and immunohistochemistry. We found that galectin-3 was overexpressed in the Caki-1, Caki-2, A704, ACHN and KPK-1 cell lines and that the expression level in CC-RCC was also significantly higher than that in renal parenchyma obtained from the same patient samples (p=0.039). Galectin-3 expression in CC-RCC with distant metastasis was also significantly higher than that in CC-RCC without distant metastasis (p=0.045). In conclusion, we revealed that galectin-3 is highly expressed in CC-RCC, especially in CC-RCC with distant metastasis, suggesting that galectin-3 may serve as a novel target molecule for predicting CC-RCC metastasis. (Keyword) Adult / Aged / Aged, 80 and over / Carcinoma, Renal Cell / Cell Line, Tumor / Female / galectin-3 / Humans / Kidney Neoplasms / Male / Middle Aged / Neoplasm Metastasis / Prognosis (Tokushima University Institutional Repository) ● Metadata: 78648 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.57.152 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20299755 ● Search Scopus @ Elsevier (PMID): 20299755 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.57.152 (Tokushima University Institutional Repository: 78648, DOI: 10.2152/jmi.57.152, PubMed: 20299755)
10.	Hirofumi Izaki, Masayuki Takahashi, Avirmed Shiirevnyamba, Ryuichi Taue, Hiroyuki Furumoto, Yoshimi Bando, Yoshihide Murakami, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Tomoharu Fukumori and Hiro-omi Kanayama : Long-term recurrence-free survivor after laparoscopic removal of solitary adrenal metastasis from endometrial adenocarcinoma., The Journal of Medical Investigation : JMI, Vol.57, No.1-2, 174-177, 2010. (Summary) Solitary adrenal metastasis from endometrial adenocarcinoma is extremely rare. We report herein the case of a laparoscopically resected solitary adrenal metastasis originating from endometrial adenocarcinoma. The patient was a 55-year-old woman who had undergone total abdominal hysterectomy for stage IIIc endometrial carcinoma, followed by 7 courses of adjuvant chemotherapy comprising carboplatin and paclitaxel. However, the patient developed an isolated right adrenal metastasis 15 months postoperatively. The solitary adrenal metastasis (diameter, 5.7 cm) was removed laparoscopically. The patient has now been in good health without recurrence for 5 years and 7 months after laparoscopic surgery. To the best of our knowledge, this is the first case of solitary adrenal metastasis originating from endometrial adenocarcinoma that is controlled for the long term by successful laparoscopic resection. (Keyword) Adenocarcinoma / Adrenal Gland Neoplasms / Endometrial Neoplasms / Female / Humans / Laparoscopy / Middle Aged / Survivors / Tomography, X-Ray Computed (Tokushima University Institutional Repository) ● Metadata: 77529 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.57.174 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20299759 ● Search Scopus @ Elsevier (PMID): 20299759 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.57.174 (Tokushima University Institutional Repository: 77529, DOI: 10.2152/jmi.57.174, PubMed: 20299759)
11.	Takahiro Koizumi, Hiroyoshi Nakatsuji, Tomoya Fukawa, Shiirevnyamba Avirmed, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : The role of actinin-4 in bladder cancer invasion., Urology, Vol.75, No.2, 357-364, 2009. (Summary) To examine actinin-4 expression levels in bladder cancer, in particular its levels during cellular growth and invasion. Actinin-4 is an actin-binding protein that is associated with cell motility and cancer metastasis. (Keyword) Actinin / Cell Proliferation / Humans / Neoplasm Invasiveness / RNA, Messenger / Tumor Cells, Cultured / Urinary Bladder Neoplasms (Link to Publication Site) ● Publication site (DOI): 10.1016/j.urology.2009.09.037 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19969329 ● Search Scopus @ Elsevier (PMID): 19969329 ● Search Scopus @ Elsevier (DOI): 10.1016/j.urology.2009.09.037 (DOI: 10.1016/j.urology.2009.09.037, PubMed: 19969329)

Review, Commentary:

1.	Masayuki Takahashi, Tomoya Fukawa and Hiro-omi Kanayama : 【新腎・泌尿器癌(上)-基礎・臨床研究の進歩-】腎癌腎癌の分子生物学と発癌機序遺伝子異常, Nihon Rinsho. Japanese Journal of Clinical Medicine, Vol.75, No.6, 39-46, Aug. 2017.

Proceeding of International Conference:

1.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Examination of Mid-Urethral Sling (MUS) for elderly patients over 75 years old, Athens, Oct. 2019.
2.	Masayuki Takahashi, Kei Daizumoto, Tomoya Fukawa, Yayoi Fukuhara, Ozaki Keisuke, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : The significance of insulin receptor expression to predict the resistance to VEGFR-TKIs and induce PD-L1 expression in advanced clear cell renal cell carcinoma, 2019 ASCO Genitourinary Cancers Symposium, Feb. 2019.
3.	Yasuyo Yamamoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Yoshihiro Tsuruo, Kei Daizumoto and Hidehisa Mori : Usefulness of Fresh Frozen Cadaver and Animal Models for Surgical Training in Laparoscopic Sacrocolpopexy, The 36th World Congress of Endourology, Paris, Sep. 2018.
4.	Masayuki Takahashi, Kei Daizumoto, Yayoi Fukuhara, Ozaki Keisuke, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Correlation of the insulin receptor expression changes by the administration of VEGFR-TKI and the resistance to the VEGFR-TKI in clear cell renal cell carcinoma, 113th American Urological Association Annual meeting, May 2018.
5.	Hidehisa Mori, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : What is an appropriate definition of IPSS resolution that correlates closely with QOL recovery after prostate brachytherapy?, The Journal of Urology, Vol.199, No.4, e274, San Francisco, May 2018. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.juro.2018.02.718 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.juro.2018.02.718 (DOI: 10.1016/j.juro.2018.02.718)
6.	Toyomasa Katagiri, Kei Daizumoto, Tetsuro Yoshimaru, Yosuke Matsushita, Tomoya Fukawa, Ono Masaya and Hiro-omi Kanayama : DDX31 cooperates with mutant p53 and EGFR to promote the multistep progression of invasive bladder cancer, American Association For Cancer Research ANNUAL MEETING 2018, Chicago, Apr. 2018.
7.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Masayuki Takahashi : Long-term Administration of Mirabegron in the Treatment of Overactive Bladder, 37th Congress of the Societe Internationale d'Urologie, Lisbon, Oct. 2017.
8.	Hidehisa Mori, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Safety and efficacy of low-dose-rate brachytherapy for localized prostate cancer in elderly patients, Lisbon, Oct. 2017.
9.	T Shintani, K Daizumoto, Tomoya Fukawa, H Nakatsuji, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : HGF-MET-MMP and VEGF-C signaling as a potential target for invasive bladder cancer therapy, 2017 European association of Urology, London, Mar. 2017.
10.	Tomoharu Fukumori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Galectin-3 is involved in the progression of castration-resistant prostate cancer through the regulation of tumor invasion, angiogenesis and androgen receptor signaling., 2017 European association of Urology, London, Mar. 2017.
11.	Masayuki Takahashi, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Correlation of insulin receptor expression with efficacy of axitinib in patients with advanced renal cell carcinoma, 2017 Genitourinary Cancers Symposium, Feb. 2017.
12.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Clinical characteristics differ in ulcerative and non-ulcerative subtypes of interstitial cystitis/ bladder pain syndrome, International Continence Society, Tokyo, Sep. 2016.
13.	Terumichi Shintani, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : Low expression of Toll like receptor 4 is associated with squamous differentiation in bladder cancer., The American Urological Association, Inc. 111th Annual Meeting, May 2016.
14.	Tomoharu Fukumori, Dondoo Tsogt-Ochir, K Daizumoto, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : Galectin-3 is a therapeutic target for castration-resistant prostate cancer., The American Urological Association, Inc. 110th Annual Meeting, New Orleans, May 2015.
15.	Toyomasa Katagiri, Tomoya Fukawa, Taisuke Matsuo and Hiro-omi Kanayama : DDX31 regulates p53 tumor suppressive activity in renal cell carcinomas, Amerian Association for Cancer Research (AACR) Annal Meeting 2013, Washington, D.C., Apr. 2013.
16.	Masayuki Takahashi, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : THE LOW TRANS-SCROTAL ORCHIDOPEXY FOR UNDESCENDED TESTES, The 32nd Congress of the Société Internationale dUrologie, Oct. 2012.
17.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Clinical significance of neoadjuvant combined androgen blockade before I-125 prostate brachytherapy in patients with localized prostate cancer., 32th Congress of the Societe Internationale dUrologie, Oct. 2012.
18.	Tomokazu Senzaki, Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Predictive factors for urinary morbidity after I-125 prostate brachytherapy, 32th Congress of the Societe Internationale dUrologie, Oct. 2012.
19.	T Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Clinical significance of neoadjuvant combined androgen blockade before I-125 prostate brachytherapy in patients with localized prostate cancer., 32th Congress of the Societe Internationale dUrologie, 2012.
20.	Tomoya Fukawa, Ono Masaya, Hisanori Uehara, Taisuke Matsuo, Nakamura Yusuke, Hiro-omi Kanayama and Toyomasa Katagiri : Identification and characterization of RCCDH as a novel molecular target for clear renal cell carcinoma., 70th Annual Meeting of the Japanese Cancer Association, Oct. 2011.
21.	Masayuki Takahashi, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : A multi-center randomized Phase II study of the second-line maximum androgen blockade with an alternative antiandrogen combined with tegafur-uracil (UFT®) for prostate cancer with relapse after initial hormonal therapy, 2011 Annual Meeting of American Society of Clinical Oncology, Jun. 2011.

Proceeding of Domestic Conference:

1.	塩﨑啓登, 堀克仁, Yutaro Sasaki, Kei Daizumoto, Kazuta Yamashita, Tomoya Fukawa, 中西良一, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Koichi Tomita : 未固定新鮮凍結遺体を用いたECIRSでの職業被曝低減についての検討, 第33回日本尿路結石学会, Aug. 2024.
2.	Yutaro Sasaki, Ryotaro Tomida, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi, Hiro-omi Kanayama and Koichi Tomita : ロボット支援手術時代においても，腹腔鏡手術の教育・経験の重要性は揺るがない, 第36回日本内視鏡外科学会総会, Dec. 2023.
3.	Keito Shiozaki, 堀克仁, Yutaro Sasaki, Kei Daizumoto, Tomoya Fukawa, 中西良一, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hiro-omi Kanayama and Koichi Tomita : Cadaver surgical trainingにおける内シャント造設の試み, 第53回徳島透析療法研究会, Dec. 2023.
4.	塩﨑啓登, 堀克仁, Yutaro Sasaki, Tomoya Fukawa, 中西良一, 山下太一, Koichi Tomita, 伊﨑博文 and Masayuki Takahashi : 未固定新鮮凍結遺体を用いたECIRSでの職業被曝低減についての検討, 第37回日本泌尿器内視鏡・ロボティクス学会総会, Nov. 2023.
5.	Honoka Kamakura, Madoka Uezumi, 黒澤珠希, Tomoya Fukawa, Takeshi Nikawa and Akiyoshi Uezumi : ヒト筋幹細胞を用いた筋肥大作用を有する天然由来生理活性生物の同定, 第45回日本分子生物学会年会, Dec. 2022.
6.	TANAKA Yukako, KOMATSU Rina, HIRATA Shuya, Tomoya Fukawa and Takeshi Nikawa : がん由来エクソソーム内 micro RNA によるミトコンドリア呼吸鎖複合体制御と筋萎縮発症機序の解明, 第55回日本栄養・食糧学会中国・四国支部大会, Oct. 2022.
7.	Masayuki Takahashi, Kei Daizumoto, 福田喬太郎, 安宅祐一朗, 泉和良, Yoshito Kusuhara, Tomoya Fukawa and Hiro-omi Kanayama : 進行性腎細胞癌に対するニボルマブ・イピリムマブ併用療法の検討: 多施設共同後ろ向き研究, 日本泌尿器腫瘍学会第8回, Oct. 2022.
8.	加藤廉平, 前川滋克, 加藤陽一郎, 兼平貢, 高田亮, Yosuke Matsushita, Tetsuro Yoshimaru, Tomoya Fukawa, Toyomasa Katagiri and 小原航 : 3 次元培養下における新規の癌特異分子PRELID2 の分子機能の解明, 第81回日本癌学会学術総会, Oct. 2022.
9.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshiteru Ueno, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 女性神経因性膀胱患者に対するボツリヌス毒素膀胱壁内注入療法の経験, 日本女性骨盤底医学会, Jul. 2022. (Keyword) female / 神経因性膀胱 / ボツリヌス毒素膀胱壁内注入療法
10.	堀克仁, Yutaro Sasaki, 角陸文哉, Keito Shiozaki, Kei Daizumoto, 冨田諒太郎, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 当院での未固定遺体を用いた内シャント造設術トレーニングの試み ∼生体との違いについて∼, 日本泌尿器科学会四国地方会, Jul. 2022.
11.	Yutaro Sasaki, 堀克仁, 角陸文哉, Kei Daizumoto, 上野恵輝, 冨田諒太郎, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 多診療科で行うロボット支援手術 ∼後方骨盤内臓全摘除術の1例∼, 日本泌尿器科学会四国地方会, Jul. 2022.
12.	TAKATA Miho, Iori Sakakibara, KISHIDA Kohta, FUKUSHIMA Taku, ARAKAKI Tsubasa, Takayuki Uchida, Tomoya Fukawa and Takeshi Nikawa : 骨格筋におけるAconitase2の機能解明, 第76回日本栄養・食糧学会大会, Jun. 2022.
13.	Minori Yamasaki, HIROKI Matsuki, NAKANO Wataru, Kosuke Sugiura, Tomoya Fukawa, Takayuki Uchida, Iori Sakakibara and Takeshi Nikawa : 廃用性筋萎縮におけるアコニターゼ活性の低下とその栄養学的保護, 第76回日本栄養・食糧学会大会, Jun. 2022.
14.	Yasuyo Yamamoto, Megumi Tsuda, 安宅真利花, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 当院における難治性過活動膀胱に対するボツリヌス毒素膀胱壁内注入療法の臨床的検討, 日本老年泌尿器科学会誌, Vol.35, No.1, 144, Jun. 2022. (Keyword) 難治性過活動膀胱 / ボツリヌス毒素膀胱壁内注入療法
15.	Yutaro Sasaki, 橋本啓佑, Keito Shiozaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 女性のRARCにおける膣再建の新たな手法 ∼Benz closure technique∼, 泌尿器科再建再生研究会, Jun. 2022.
16.	橋本啓佑, Yutaro Sasaki, 安宅真利花, 多田航生, 中西亮太, 吉岡拓哉, Kei Daizumoto, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : ロボット支援体腔内回腸導管造設術においてストマ造設を円滑に行うための工夫, 日本ロボット外科学会学術集会, Feb. 2022.
17.	Yutaro Sasaki, 福田喬太郎, Kei Daizumoto, Keito Shiozaki, Yoshito Kusuhara, Tomoya Fukawa, 中西良一, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, 神田和哉 and Hiro-omi Kanayama : 高齢患者(≧75歳)のロボット支援膀胱全摘除術における体腔内回腸導管造設術と尿管皮膚瘻造設術の比較, 日本泌尿器科学会総会, Dec. 2021.
18.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 当院における外来排尿自立指導の臨床的検討, The Japanese Journal of Urology, Dec. 2021.
19.	Yutaro Sasaki, Kei Daizumoto, Keito Shiozaki, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, 神田和哉 and Hiro-omi Kanayama : 「アシステントガイド」の開発体腔内回腸導管造設時の尿管ステント留置を円滑に, 日本泌尿器内視鏡学会総会, Nov. 2021.
20.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 憩室口が遠位に存在する尿道憩室摘除術における工夫, The Nishinihon Journal of Urology, Vol.83, Nov. 2021.
21.	Yasuyo Yamamoto, Kei Daizumoto, Yutaro Sasaki, Megumi Tsuda, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 夜間頻尿に対するデスモプレシンの使用経験, 日本排尿機能学会誌, Vol.32, No.1, Sep. 2021.
22.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yutaro Sasaki, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 骨盤臓器脱に対し膣閉鎖術を行った症例の検討, 日本女性骨盤底医学会, Jul. 2021.
23.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 難治性過活動膀胱に対するボツリヌス毒素膀胱壁内注入療法の初期治療経験, 日本老年泌尿器科学会誌, Vol.34, No.1, 109, May 2021.
24.	Masayuki Takahashi, Yoshito Kusuhara, Yutaro Sasaki, Kei Daizumoto, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : ロボット支援下腎盂形成術-温故創新成人水腎症に対するロボット支援腎盂形成術の初期経験, 第33回日本内視鏡外科学会総会, Mar. 2021.
25.	Yasuyo Yamamoto, Tomoya Fukawa, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 骨盤臓器脱患者に対する腹腔鏡下仙骨腟固定術前の下部尿路症状の変化, 第33回日本内視鏡外科学会総会, Mar. 2021.
26.	Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi, Tomoya Fukawa and Yoshito Kusuhara : 腎移植後のリンパ漏にリンパ管造影が効果的であった3例, 日本臨床腎移植学会, Feb. 2021.
27.	Masayuki Takahashi, Tetsuhiro Yano, Kei Daizumoto, Yutaroh Sasaki, Keisuke Ozaki, Yoshiteru Ueno, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : 転移性腎細胞癌に対するニボルマブ・イピリムマブ併用療法の初期経験, 第108回日本泌尿器科学会総会, Dec. 2020.
28.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 腹腔鏡下仙骨腟固定術前後で比較した下部尿路機能症状とQOLの変化, 第108回日本泌尿器科学会総会, Dec. 2020.
29.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 骨盤臓器脱患者に対する腹腔鏡下仙骨腟固定術前後での下部尿路症状の変化, 第82回西日本泌尿器科学会総会, Nov. 2020.
30.	Yasuyo Yamamoto, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : TOT手術時のヘガールを用いたテープ調整の有用性, 第27回日本排尿機能学会, Oct. 2020.
31.	Masayuki Takahashi, Kei Daizumoto, Tomoya Fukawa and Hiro-omi Kanayama : 転移性腎細胞癌に対するニボルマブ・イピリムマブ併用療法の初期経験, 第24回日本がん分子標的治療学会学術集会, Oct. 2020.
32.	Kei Daizumoto, Yayoi Fukuhara, Tomoya Fukawa, Toyomasa Katagiri, Hisanori Uehara, Masayuki Takahashi and Hiro-omi Kanayama : 尿路上皮癌に対するDDX31/NCL相互作用阻害による抗腫瘍効果の検討, 第79回日本癌学会学術総会, Oct. 2020.
33.	尾崎啓介, Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi and Tomoya Fukawa : -, Journal of Japanese Society for Dialysis Therapy, Vol.53, 813, Oct. 2020.
34.	Megumi Tsuda, Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 泌尿器科疾患以外の患者に対する排尿ケアチーム介入の臨床的検討, 第33回日本老年泌尿器科学会総会, Sep. 2020.
35.	Masayuki Takahashi, Kei Daizumoto, 佐々木雄太郎, 尾﨑啓介, 上野恵輝, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi and Hiro-omi Kanayama : Case report of four patients with metastatic renal cell carcinoma who received nivolumab and ipilimumab combination therapy, Oct. 2019.
36.	加藤廉平, Tomoya Fukawa, Yosuke Matsushita, Tetsuro Yoshimaru, 尾野雅哉, Kei Daizumoto, 加藤陽一郎, 小原航 and Toyomasa Katagiri : 腎癌の癌化におけるPRELID2によるミトコンドリアROS制御機構の解明, 第78回日本癌学会学術総会, Sep. 2019.
37.	Yasuyo Yamamoto, Tomoya Fukawa, Kei Daizumoto, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : RARPにおける術前残尿量と術後尿禁制の関連, 第26回日本排尿機能学会, Sep. 2019.
38.	Yasuyo Yamamoto, Tomoya Fukawa, Megumi Tsuda, Kei Daizumoto, Yoshito Kusuhara, Hidehisa Mori, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 骨盤臓器脱と膀胱憩室を同時に治療した1例, 第21回女性骨盤底医学会, Jul. 2019.
39.	Masayuki Takahashi, Kei Daizumoto, 尾﨑啓介, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 高齢腎癌患者に対する根治的腎摘除術/腎部分切除術の臨床的検討, 第50回腎癌研究会記念大会, Jul. 2019.
40.	Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Megumi Tsuda, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 排尿ケアチームが複数回介入した症例の検討, The Japanese Journal of Urology, Apr. 2019.
41.	Masayuki Takahashi, 西山美月, 福田喬太郎, Kei Daizumoto, 尾﨑啓介, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 小児膀胱尿管逆流症に対する気膀胱下Cohen法の初期治療経験, 第107回日本泌尿器科学会総会, Apr. 2019.
42.	尾崎啓介, Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi and Tomoya Fukawa : -, 日本臨床腎移植学会抄録集, 249, Feb. 2019.
43.	Yasuyo Yamamoto, Yoshito Kusuhara, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Yoshihiro Tsuruo : 腹腔鏡下仙骨膣固定術(LSC: Laparoscopic Sacrocollpopexy)導入にむけたトレーニング, 第31回日本内視鏡外科学会, Dec. 2018.
44.	Masayuki Takahashi, Kei Daizumoto, Ozaki Keisuke, Tsuda Megumi, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Clinicopathological study of the elderly patients with renal cell carcinoma who underwent radical/partial nephrectomy, 第56回日本癌治療学会学術集会, Oct. 2018.
45.	Masayuki Takahashi, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : CAPDカテーテル大網嵌入に対し腹腔鏡下に大網除去，カテーテル腹壁固定した小児の1症例, 第24回腹膜透析医学会学術集会・総会, Oct. 2018.
46.	Masayuki Takahashi, Kei Daizumoto, Yayoi Fukuhara, Minoru Kowada, Yoshimi Bando, Tomoya Fukawa, Tomoharu Fukumori and Hiro-omi Kanayama : The significance of insulin receptor expression in vascular endothelial cells of clear cell renal cell carcinoma, 第77回日本癌学会学術集会, Sep. 2018.
47.	加藤廉平, Tomoya Fukawa, Tetsuro Yoshimaru, Yosuke Matsushita, 尾野雅哉, Kei Daizumoto, 加藤陽一郎, 小原航 and Toyomasa Katagiri : Critical roles of mitochondrial PRELID2 for renal carcinogenesis, 第77回日本癌学会学術総会, Sep. 2018.
48.	Kei Daizumoto, Tetsuro Yoshimaru, Yosuke Matsushita, Tomoya Fukawa, Hisanori Uehara, 尾野雅哉, Masato Komatsu, Hiro-omi Kanayama and Toyomasa Katagiri : Crucial roles of DDX31 as related to the status of TP53 in bladder cancer progression, 第77回日本癌学会学術総会, Sep. 2018.
49.	Kunihisa Yamaguchi, Hiro-omi Kanayama, Masayuki Takahashi, Yasuyo Yamamoto and Tomoya Fukawa : タクロリムスの血中濃度上昇に術後疼痛に対するフェンタニルの影響が示唆された3例, Japanese Journal of Transplantation, Vol.53, 479, Sep. 2018.
50.	Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Yoshihiro Tsuruo : 腹腔鏡下仙骨膣固定術導入にむけたトレーニング, 第20回日本女性骨盤底医学会, Jul. 2018.
51.	Masayuki Takahashi, Kei Daizumoto, Keisuke Ozaki, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : ニボルマブ投与中にhyper-progressionが疑われた淡明細胞型腎細胞癌の1例, 第49回腎癌研究会, Jul. 2018.
52.	Masayuki Takahashi, Keisuke Ozaki, Yoshito Kusuhara, 福田喬太郎, 西山美月, Kei Daizumoto, Megumi Tsuda, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 高齢の腎癌患者に対する手術, 第31回日本老年泌尿器科学会, May 2018.
53.	Yasuyo Yamamoto, Kei Daizumoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : TOT術後の過活動膀胱(OAB)治療に関する検討, 第106回日本泌尿器科学会総会, Apr. 2018.
54.	Hidehisa Mori, Tomoharu Fukumori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : IPSS resolution, Apr. 2018.
55.	Masayuki Takahashi, Kei Daizumoto, Yayoi Fukuhara, Ozaki Keisuke, Megumi Tsuda, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : Correlation of the insulin receptor expression changes by the administration of VEGFR-TKI and the resistance to the VEGFR-TKI in clear cell renal cell carcinoma, 第106回日本泌尿器科学会総会, Apr. 2018.
56.	Kei Daizumoto, Masayuki Takahashi, Taishi Miyazaki, Yayoi Fukuhara, Yoshito Kusuhara, Tomoya Fukawa, Tomoharu Fukumori and Hiro-omi Kanayama : 淡明細胞型腎細胞癌・周囲血管におけるインスリンレセプターの発現とVEGFR阻害薬の治療効果との関連性, The 27th Japanese Society for Mollecular and Cellular Urology, Feb. 2018.
57.	Masayuki Takahashi, 大豆本圭, 尾崎啓介, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 新規導入施設における気膀胱下Cohen法の問題点と工夫, 第31回日本泌尿器内視鏡学会総会, Nov. 2017.
58.	Masayuki Takahashi, 大豆本圭, 尾崎啓介, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : アキシチニブ抵抗性バイオマーカーとしての腎癌組織中インスリンレセプター発現, 第55回日本癌治療学会学術集会, Oct. 2017.
59.	Tomoharu Fukumori, Hidehisa Mori, Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 高リスク限局性前立腺癌に対する I-125 密封小線源療法の治療成績と生化学的再発予測因子の検討, 第55回日本癌治療学会学術集会, Oct. 2017.
60.	大豆本圭, Tetsuro Yoshimaru, Tomoya Fukawa, Hisanori Uehara, 尾野雅哉, Masato Komatsu, Hiro-omi Kanayama and Toyomasa Katagiri : 筋層浸潤性膀胱癌の多段階進展機構におけるDDX31, Mutant p53, EGFR Axisの役割解明, 第76回日本癌学会学術総会, Sep. 2017.
61.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : TOT術後の過活動膀胱(OAB)治療に関する検討, 第24回日本排尿機能学会, Sep. 2017.
62.	加藤廉平, Tomoya Fukawa, Tetsuro Yoshimaru, Yosuke Matsushita, 尾野雅哉, 小原航 and Toyomasa Katagiri : 腎癌の癌化におけるPRELID2の重要な役割, 第76回日本癌学会学術総会, Sep. 2017.
63.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 排尿障害から診断を得た多系統萎縮症症例, The Japanese Journal of Urology, Apr. 2017.
64.	Kei Daizumoto, Yuichiro Atagi, Chizuru Kotoh, Minoru Kowada, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : ロボット支援前立腺全摘術後の尿失禁と内閉鎖筋体積の関連性の検討, The 105th Annual Meeting of the Japanese Urological Association, Apr. 2017.
65.	Masayuki Takahashi, 安宅祐一郎, 宇都宮聖也, 大豆本圭, 津田恵, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : アキシチニブ投与患者における腎癌組織中のインスリンレセプター発現のバイオマーカーとしての意義, 第105回日本泌尿器科学会総会, Apr. 2017.
66.	Tomoharu Fukumori, Tomoya Fukawa, Yoshito Kusuhara, Hidehisa Mori, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : The mechanism of tumor progression in prostate cancer by galectin-3 based on the gene profile, 第105回日本泌尿器科学会総会, Apr. 2017.
67.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 地方での泌尿器科医療の魅力を上げるには?四国内でのsubspecialty獲得への大学を超えた連携の提言, 第100回四国地方会, Vol.79, No.6, 202, Jan. 2017.
68.	Yasuyo Yamamoto, Yoshito Kusuhara, Tomoya Fukawa, Hidehisa Mori, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 麻酔下膀胱水圧拡張術を施行した間質性膀胱炎の検討, 第16回間質性膀胱炎研究会, Jan. 2017.
69.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 当院で加療した高齢者陰唇癒着症の検討, 第23回日本排尿機能学会, Dec. 2016.
70.	Yasuyo Yamamoto, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : TOT手術後に再手術を施行した3症例, 第68回西日本泌尿器科学会総会, Nov. 2016.
71.	Tomoharu Fukumori, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Tomoharu Fukumori : ロボット支援手術でのシステムトラブルの検討, 第30回日本泌尿器内視鏡学会, Nov. 2016.
72.	Tomoharu Fukumori, Hidehisa Mori, Yoshito Kusuhara, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : I-125, 第54回癌治療学会学術集会, Oct. 2016.
73.	Masayuki Takahashi, 大豆本圭, Yoshito Kusuhara, Tomoya Fukawa, Tomoharu Fukumori and Hiro-omi Kanayama : 腎がん分子標的治療の解析進行性腎細胞癌におけるアキシチニブの有効性とインスリンレセプター発現の関連性, 第54回日本癌治療学会学術集会, Oct. 2016.
74.	Tomoharu Fukumori, Yoshito Kusuhara, Hidehisa Mori, Tomoya Fukawa, Terumichi Shintani, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 去勢抵抗性前立腺癌患者に対する新規薬剤(アビラテロン，エンザルタミド)の初期使用経験, 第104回日本泌尿器科学会総会, Apr. 2016.
75.	Tomoharu Fukumori, Tomoya Fukawa, 大豆本圭, 津田恵, 井内俊輔, Yoshito Kusuhara, Hidehisa Mori, Jun-ichiro Kagawa, Masatsugu Komori, Kunihisa Yamaguchi, Yasuyo Yamamoto, Masayuki Takahashi and Hiro-omi Kanayama : 去勢抵抗性前立腺癌患者におけるエンザルタミドの初期使用経験, 第103回日本泌尿器科学会総会, Apr. 2016.
76.	Tomoharu Fukumori, Hidehisa Mori, 赤沢早紀, 大豆本圭, 津田恵, Yoshito Kusuhara, Terumichi Shintani, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺癌密封小線源療法後のPSA再発予測因子の検討, 第67回西日本泌尿器科学会総会, Nov. 2015.
77.	Masayuki Takahashi, 赤澤早紀, 大豆本圭, 津田恵, Yoshito Kusuhara, Hidehisa Mori, Terumichi Shintani, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : 当科における進行性腎細胞癌に対するアキシチニブの治療成績, 第53回日本癌治療学会学術総会, Oct. 2015.
78.	Tomoharu Fukumori, Hidehisa Mori, Takashi Kawanaka, Akiko Kubo, Shunsuke Furutani, 大豆本圭, 津田恵, Yoshito Kusuhara, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : I-125密封小線源療法のPSA再発症例の臨床的検討, 第53回日本癌治療学会学術集会, Oct. 2015.
79.	大豆本圭, Masato Komatsu, Ryuichiro Kimura, Tetsuro Yoshimaru, Hisanori Uehara, 尾野雅哉, Tomoya Fukawa, Hiro-omi Kanayama and Toyomasa Katagiri : P53変異型膀胱癌におけるDEAD box polypeptide31(DDX31)の機能解明, 第74回日本癌学会学術総会, Oct. 2015.
80.	大豆本圭, Masato Komatsu, Tetsuro Yoshimaru, Hisanori Uehara, Tomoya Fukawa, Hiro-omi Kanayama and Toyomasa Katagiri : 核小体がんタンパク質BCRG1は膀胱癌の進行に関連している, 第73回日本癌学会学術総会, Sep. 2014.
81.	Masayuki Takahashi, 大豆本圭, Masatsugu Komori, Jun-ichiro Kagawa, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori and Hiro-omi Kanayama : ドセタキセル70サイクル以上の投与により長期生存が得られた進行性前立腺癌の2例, 第52回日本癌治療学会学術集会, Aug. 2014.
82.	大豆本圭, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 両側腎腫瘍症例を発端者としたBirt-Hogg-Dube症候群の一家系, 日本泌尿器科総会, Apr. 2014.
83.	Masayuki Takahashi, Masatsugu Komori, Jun-ichiro Kagawa, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Hisaya Takahashi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 分子標的薬投与中に腸管穿孔をおこした有転移腎癌の2例, 第51回日本癌治療学会学術集会, Oct. 2013.
84.	Yasuyo Yamamoto, Tomoharu Fukumori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Hisaya Takahashi, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 第25回日本老年泌尿器科学会市民公開講座「おしっこの悩みに答えます∼出ない・漏れる・溜まらない∼」のアンケート結果, 日本老年泌尿器科学会誌, Vol.26, No.1, 88, May 2013.
85.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Masatsugu Komori, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 高齢(75歳以上)前立腺癌の診断および治療戦略を考える∼放射線治療の適応と照射方法∼, 第26回日本老年泌尿器科学会, May 2013.
86.	Tomoharu Fukumori, Jun-ichiro Kagawa, Masatsugu Komori, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Hisaya Takahashi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺肥大症に対するデュタステリド投与1年の臨床的検討∼早期の治療効果について∼, 日本泌尿器科学会総会, Apr. 2013.
87.	Masayuki Takahashi, 小森正嗣, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 小児低形成腎/無機能腎に対する腹腔鏡下腎摘除術の検討, 日本泌尿器内視鏡学会, Nov. 2012.
88.	Tomoharu Fukumori, Tomokazu Senzaki, 小森正嗣, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : Efficacy and safety of dose escalation in I-125 prostate, 第26回日本泌尿器内視鏡学会総会, Nov. 2012.
89.	Tomoya Fukawa, Ono Masaya, Taisuke Matsuo, Hisanori Uehara, Nakamura Yusuke, Hiro-omi Kanayama and Toyomasa Katagiri : RCCDH Regulates p53 Tumor suppressor activity in renal cell carcinomas., The 71th Annual Meeting of the Japanese Cancer Association, Sep. 2012.
90.	Hiroyoshi Nakatsuji, アビルメードシーレンヤンバ, Tomoya Fukawa, Masayuki Takahashi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : The involvement of Plakophilin in bladder cancer invasion, 日本癌学会総会, Sep. 2012.
91.	Kunihisa Yamaguchi, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Hiro-omi Kanayama, 悦子李, 菅政治 and 岡本賢二郎 : 徳島大学における生体腎移植初回例の報告, Japanese Journal of Transplantation, Vol.46, No.6, 696, Aug. 2012. (Keyword) *腎臓移植
92.	Kunihisa Yamaguchi, Tomokazu Senzaki, Tomoya Fukawa, Hirofumi Izaki and Hiro-omi Kanayama : 徳島県における献腎摘出の現状, Jun. 2012.
93.	Yasuyo Yamamoto, Tomoharu Fukumori, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 高齢者に対する尿失禁手術(TOT手術)の臨床的検討, 日本老年泌尿器科学会, Jun. 2012.
94.	Masayuki Takahashi, 瀬戸公介, 津田恵, Tomokazu Senzaki, 小森政嗣, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 低形成腎/無機能腎に対する腹腔鏡下腎摘除術の臨床的検討, 日本泌尿器科学会総会, Apr. 2012.
95.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺癌密封小線源療法後の排尿障害予測因子の検討, 第100回日本泌尿器科学会総会, Apr. 2012.
96.	Tomoharu Fukumori, Shunsuke Furutani, Hiroyoshi Nakatsuji, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 限局性前立腺癌に対する密封小線源療法のリスク分類別治療成績, 第27回前立腺シンポジウム, Dec. 2011.
97.	津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, 岸本大輝, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : MIBG療法を施行した悪性褐色細胞腫の1例, The Nishinihon Journal of Urology, Vol.73, No.9, 503, Nov. 2011. (Keyword) *褐色細胞腫(薬物療法,外科的療法)
98.	Masayuki Takahashi, 辻岡卓也, 中島英, 津田恵, Tomokazu Senzaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 進行性腎細胞癌に対する薬物療法いつ，何を，どう使う? 進行性腎癌に対する分子標的薬のsequential therapy, The Nishinihon Journal of Urology, Vol.73, 86, Nov. 2011. (Keyword) *腎細胞癌(薬物療法)
99.	辻岡卓也, 上野恵輝, Masahiko Takemura, 津田恵, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Masa-aki Nishitani : 血液透析患者に対してGemcitabine/Carboplatin併用療法を施行した浸潤性膀胱癌の一例, The Nishinihon Journal of Urology, Vol.73, 127, Nov. 2011. (Keyword) *Carboplatin(治療的利用)
100.	Masahiko Takemura, 中島英, 富田諒太郎, 津田恵, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and 三浦浩康 : 不完全重複腎盂尿管に合併した上部尿路結石に対してf-TULを施行した2例, The Nishinihon Journal of Urology, Vol.73, 143, Nov. 2011. (Keyword) *砕石術
101.	Hirofumi Izaki, Masahiko Takemura, Masayuki Takahashi, 中辻弘能, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoya Fukawa, 津田恵, Tomoteru Kishimoto, 上野恵輝, Tomoharu Fukumori, Hiro-omi Kanayama and 三浦浩康 : 徳島大学におけるf-TULの試み導入期に注意したいこと, The Nishinihon Journal of Urology, Vol.73, 143, Nov. 2011. (Keyword) 病的狭窄(治療)
102.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Shunsuke Furutani, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hirofumi Izaki, Masayuki Takahashi, Hitoshi Ikushima and Hiro-omi Kanayama : 前立腺密封小線源療法前のcombined androgen blockade(CAB)療法の臨床的検討, The Journal of Japan Society for Cancer Therapy, Vol.46, No.2, 677, Oct. 2011. (Keyword) *Androgen Antagonists(治療的利用)
103.	Masayuki Takahashi, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 当科における進行性/転移性腎腫瘍患者に対するエべロリムスの使用経験, 第49回日本癌治療学会学術集会, Oct. 2011.
104.	中島英, 上野恵輝, Masahiko Takemura, 津田恵, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Masa-aki Nishitani : 血液透析患者に対してGemcitabine/Carboplatin併用療法を施行した浸潤性膀胱癌の一例, 日本泌尿器科学会四国地方会, Jul. 2011.
105.	冨田諒太郎, Kunihisa Yamaguchi, 上野恵輝, 中島英, 瀬戸公介, 辻岡卓也, 津田恵, Tomoya Fukawa, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Masahiko Takemura, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 肉眼的血尿から貧血をきたした悪性黒色腫の膀胱転移に対するTURの経験, 日本泌尿器科学会四国地方会, Jul. 2011.
106.	Tomoya Fukawa, Taisuke Matsuo, 中村祐輔, Hiro-omi Kanayama and Toyomasa Katagiri : 腎細胞癌新規分子標的遺伝子RCCDPの同定およびその機能解析, 第15回日本がん分子標的治療学会, Jun. 2011.
107.	アビルメドシーレンヤンバ, Hiroyoshi Nakatsuji, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : Participation of N-caderin in bladder cancer, 日本泌尿器科学会総会, Apr. 2011.
108.	Masahiko Takemura, 瀬戸公介, 辻岡拓也, 津田恵, Tomoya Fukawa, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Yasuyo Yamamoto, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, The Japanese Journal of Urology, Vol.103, No.2, 369, Apr. 2011. (Keyword) *血液透析
109.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, 津田恵, Masahiko Takemura, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 前立腺癌密封小線源療法後のPSA failure 症例の臨床的検討, 日本泌尿器科学会総会, Apr. 2011.
110.	Hirofumi Izaki, Masayuki Takahashi, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Tomoharu Fukumori and Hiro-omi Kanayama : いかに泌尿器科入局者を増やすか!地方大学の卒前教育の取り組み, 日本泌尿器科学会総会, Apr. 2011.
111.	Hiroyoshi Nakatsuji, シーレンヤンバアビルメド, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : HGFによる膀胱がん浸潤亢進におけるToll like receptor 4 (TLR4) の関与, 日本泌尿器科学会総会, Apr. 2011.
112.	Masayuki Takahashi, Hiroaki Kawano, 村上佳秀, 須藤泰史, 稲井徹, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 去勢抵抗性前立腺癌に対する抗アンドロゲン剤抗体療法とUFT併用療法の有効性と安全性に関する無作為化第Ⅱ相臨床試験, 日本泌尿器科学会総会, Apr. 2011.
113.	Tomoteru Kishimoto, 上野恵輝, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama and Susumu Kagawa : 非虚血性持続勃起症の1例, 日本性機能学会東部総会, Mar. 2011.
114.	Kunihisa Yamaguchi, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori and 金山博文 : 前立腺癌長期分泌療法施行術における治療中止後のPSAおよびテストステロン値の検討, 中国四国前立腺疾患研究会, Feb. 2011.
115.	Masahiko Takemura, 津田恵, Tomoya Fukawa, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Yasuyo Yamamoto, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 2010年徳島大学病院泌尿器科臨床統計, 日本泌尿器科学会四国地方会, Jan. 2011.
116.	上野恵輝, Tomoteru Kishimoto, 津田恵, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 非虚血性持続勃起症の一例, 日本泌尿器科学会四国地方会, Jan. 2011.
117.	津田恵, Tomoteru Kishimoto, Masahiko Takemura, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : 射精障害を契機に発見された汎下垂体機能低下症の1例, The Nishinihon Journal of Urology, Vol.72, 121, Nov. 2010. (Keyword) Cortisone(治療的利用)
118.	Yasuyo Yamamoto, 津田恵, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Ryuichi Taue and Masa-aki Nishitani : 徳島大学病院における膀胱水圧拡張術を施行した間質性膀胱炎の検討, The Nishinihon Journal of Urology, Vol.72, 169, Nov. 2010. (Keyword) 拡張法
119.	Masahiko Takemura, Tomoya Fukawa, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Yasuyo Yamamoto, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 腹腔鏡下右副腎摘除術と小脳血管芽腫摘出術を一期的に施行したvon Hippel-Lindau病の1例, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 206, Oct. 2010.
120.	Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 248, Oct. 2010. (Keyword) 血液透析
121.	Tomoteru Kishimoto, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 精嚢嚢胞状拡張を伴った射精管閉塞の1例, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 249, Oct. 2010.
122.	Hirofumi Izaki, Masayuki Takahashi, Tomoya Fukawa, Masahiko Takemura, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Yasuyo Yamamoto, Tomoteru Kishimoto, Tomoharu Fukumori and Hiro-omi Kanayama : 転移性副腎腫瘍に対する腹腔鏡手術議論のポイント, Japanese Journal of Endourology and ESWL, Vol.23, No.3, 162, Oct. 2010. (Keyword) 腎細胞癌(転移性,外科的療法)
123.	Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, 24 Endourology ESWL, Vol.23, No.3, 248, Oct. 2010. (Keyword) *血液透析
124.	岸本大輝, Tomoya Fukawa, Masahiko Takemura, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 精嚢嚢胞状拡張を伴った射精管閉塞の1例, 24 Endourology ESWL, Oct. 2010. (Keyword) 精嚢
125.	Tomoya Fukawa, Taisuke Matsuo, 三木恒治, 中村祐輔, Hiro-omi Kanayama and Toyomasa Katagiri : Identiffication and characterization of RCCMP as a novel molecular target for clear cell-renal cell carcinoma, 69th Annual Meeting of the Japanese Cancer Association, Sep. 2010.
126.	Hiroyoshi Nakatsuji, シーレンヤンバアビルメード, Tomoya Fukawa, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 乳糜尿に対して後腹膜鏡下腎周囲リンパ管遮断術を施行した一例, 日本癌学会学術総会, Sep. 2010.
127.	津田恵, Tomoya Fukawa, Masahiko Takemura, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : BCG膀胱内注入療法後に生じたReiter症候群の1例, 日本泌尿器科学会四国地方会, Jul. 2010.
128.	Masahiko Takemura, 津田恵, Tomoya Fukawa, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 腹腔鏡下右副腎摘除術と小脳血管芽腫摘出術を一期的に施行したvon Hippel-Lindau病の1例, 日本泌尿器科学会四国地方会, Jul. 2010.
129.	Hirofumi Izaki, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Kunihisa Yamaguchi, Tomoteru Kishimoto, Masayuki Takahashi, Tomoharu Fukumori, Takushi Naroda, 木内慎一郎, 高橋久弥, 赤沢誠二, Masahiko Takemura, 林秀樹, 水田耕司, 橋本寛文, 榊学, 浜尾巧 and Hiro-omi Kanayama : 透析患者の泌尿器科悪性疾患に対する体腔鏡手術の臨床的検討, Journal of Japanese Society for Dialysis Therapy, Vol.43, No.Suppl.1, 370, Jun. 2010.
130.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : 高齢者に対する前立腺癌密封小線源療法の臨床的検討, 日本老年泌尿器科学会誌, Vol.23, 75, May 2010. (Keyword) *近距離照射治療法
131.	Masayuki Takahashi, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 当科における80歳以上の腎腫瘍患者の臨床的検討, 第23回日本老年泌尿器科学会, May 2010.
132.	Masayuki Takahashi, 山本洋之, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 進行性腎癌に対するNeoadjuvant療法進行性腎癌に対するNeoadjuvant療法のUpdate, The Japanese Journal of Urology, Vol.101, No.2, 152, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205072211840 (CiNii: 1390001205072211840)
133.	Masayuki Takahashi, 山本洋之, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : DOUBLE-PHASE HELICAL CTによる腎腫瘍組織型予測, The Japanese Journal of Urology, Vol.101, No.2, 214, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205073840256 (CiNii: 1390001205073840256)
134.	Tomoharu Fukumori, Hiroyoshi Nakatsuji, 山本洋之, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi and Hiro-omi Kanayama : I-125前立腺癌密封小線源療法後の排尿障害の予測因子の検討, The Japanese Journal of Urology, Vol.101, No.2, 242, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282680048519296 (CiNii: 1390282680048519296)
135.	アビルメッドシーレブニヤンバ, Hisanori Uehara, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori, Keisuke Izumi and Hiro-omi Kanayama : Change of Gene Expressions of Prostate Cancer Cells by Direct Contact with Osteoblasts, The Japanese Journal of Urology, Vol.101, No.2, 369, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390001205072421504 (CiNii: 1390001205072421504)
136.	Takahiro Koizumi, 山本洋之, 湯浅明人, Tomoya Fukawa, Kunihisa Yamaguchi, Yasuyo Yamamoto, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 転移を有さない再燃前立腺癌に対する放射線療法の検討, The Japanese Journal of Urology, Vol.101, No.2, 448, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282680047830912 (CiNii: 1390282680047830912)
137.	Hiroyoshi Nakatsuji, アビルメッドシーレブニヤンバ, 湯浅明人, 山本洋之, Tomoya Fukawa, Takahiro Koizumi, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 膀胱癌浸潤におけるプラコフィリン2の関与, The Japanese Journal of Urology, Vol.101, No.2, 527, Apr. 2010. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282680050442240 (CiNii: 1390282680050442240)
138.	Hiroyoshi Nakatsuji, Avirmed Shiirevnyamba, 湯浅明人, 山本洋之, Tomoya Fukawa, Takahiro Koizumi, 山本泰代, Kunihisa Yamaguchi, Tomoteru Kishimoto, Hirofumi Izaki, Masayuki Takahashi, Tomoharu Fukumori and Hiro-omi Kanayama : 膀胱がん浸潤におけるプラコフィリン2の関与, 泌尿器科分子・細胞研究会, Feb. 2010.
139.	Tomoteru Kishimoto, 山本洋之, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Hirofumi Izaki, Tomoharu Fukumori, Hiro-omi Kanayama and 細川忠宣 : 2009年徳島大学泌尿器科臨床統計, 日本泌尿器科学会四国地方会, Jan. 2010.
140.	湯浅明人, 山本洋之, Tomoya Fukawa, Takahiro Koizumi, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 回腸導管より出血を繰り返したストーマ静脈瘤の1例, 日本泌尿器科学会四国地方会, Jan. 2010.
141.	山本洋之, Masayuki Takahashi, 湯浅明人, Tomoya Fukawa, Takahiro Koizumi, 山本泰代, Kunihisa Yamaguchi, Hiroyoshi Nakatsuji, Tomoteru Kishimoto, Hirofumi Izaki, Tomoharu Fukumori and Hiro-omi Kanayama : 乳糜尿に対して後腹膜鏡下腎周囲リンパ管遮断術を施行した一例, 日本泌尿器科学会四国地方会, Jan. 2010.

Et cetera, Workshop:

1.	Yoshito Kusuhara, 大豆本圭, 尾崎啓介, 津田恵, Hidehisa Mori, Tomoya Fukawa, Yasuyo Yamamoto, Kunihisa Yamaguchi, Tomoharu Fukumori, Masayuki Takahashi and Hiro-omi Kanayama : ロボット支援腹腔鏡下腎盂形成術の初期経験, 第26回中国四国前立腺・腎尿路疾患研究会, Mar. 2018.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

RCC Precision Medicine Project using PDX models (Project/Area Number: 23K08736 )
Elucidation of metabolic regulation in muscle cells by cancer-derived exosomes to overcome cancer cachexia (Project/Area Number: 23K06613 )
Development of a Novel Therapy for Cancer Cachexia by Targeting Metabolic Changes in Skeletal muscle (Project/Area Number: 19K07731 )
Exosome-mediated muscle atrophy and new therapeutic approaches for cancer cachexia (Project/Area Number: 19H03516 )
Elucidation of the molecular mechanism of galectin-3 in the progression of urological cancer (Project/Area Number: 18K09136 )
Search by Researcher Number (70564342)

Associate Professor : Fukawa, Tomoya

Research

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)